1
|
Tane T, Selak V, Eggleton K, Harwood M. Drivers of access to cardiovascular health care for rural Indigenous Peoples: a scoping review. Rural Remote Health 2024; 24:8674. [PMID: 38697785 DOI: 10.22605/rrh8674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2024] Open
Abstract
INTRODUCTION Māori (the Indigenous Peoples of Aotearoa New Zealand) are disproportionately represented in cardiovascular disease (CVD) prevalence, morbidity and mortality rates, and are less likely to receive evidence-based CVD health care. Rural Māori experience additional barriers to treatment access, poorer health outcomes and a greater burden of CVD risk factors compared to Non-Māori and Māori living in urban areas. Importantly, these inequities are similarly experienced by Indigenous Peoples in other nations impacted by colonisation. Given the scarcity of available literature, a systematic scoping review was conducted on literature exploring barriers and facilitators in accessing CVD health care for rural Māori and other Indigenous Peoples in nations impacted by colonisation. METHODS The review was underpinned by Kaupapa Māori Research methodology and was conducted utilising Arksey and O'Malley's (2005) methodological framework. A database search of MEDLINE (OVID), PubMed, Embase, SCOPUS, CINAHL Plus, Australia/New Zealand Reference Centre and NZResearch.org was used to explore empirical research literature. A grey literature search was also conducted. Literature based in any healthcare setting providing care to adults for CVD was included. Rural or remote Indigenous Peoples from New Zealand, Australia, Canada, and the US were included. Literature was included if it addressed cardiovascular conditions and reported barriers and facilitators to healthcare access in any care setting. RESULTS A total of 363 articles were identified from the database search. An additional 19 reports were identified in the grey literature search. Following screening, 16 articles were included from the database search and 5 articles from the grey literature search. The literature was summarised using the Te Tiriti o Waitangi (Treaty of Waitangi) Framework principles: tino rangatiratanga (self-determination), partnership, active protection, equity and options. Themes elucidated from the literature were described as key drivers of CVD healthcare access for rural Indigenous Peoples. Key driver themes included input from rural Indigenous Peoples on healthcare service design and delivery, adequate resourcing and support of indigenous and rural healthcare services, addressing systemic racism and historical trauma, providing culturally appropriate health care, rural Indigenous Peoples' access to family and wellbeing support, rural Indigenous Peoples' differential access to the wider social determinants of health, effective interservice linkages and communication, and equity-driven and congruent data systems. CONCLUSION The findings are consistent with other literature exploring access to health care for rural Indigenous Peoples. This review offers a novel approach to summarising literature by situating the themes within the context of equity and rights for Indigenous Peoples. This review also highlighted the need for further research in this area to be conducted in the context of Aotearoa New Zealand.
Collapse
Affiliation(s)
- Tāria Tane
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Kyle Eggleton
- Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Matire Harwood
- Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| |
Collapse
|
2
|
Holt A, Batinica B, Liang J, Kerr A, Crengle S, Hudson B, Wells S, Harwood M, Selak V, Mehta S, Grey C, Lamberts M, Jackson R, Poppe KK. Development and validation of cardiovascular risk prediction equations in 76 000 people with known cardiovascular disease. Eur J Prev Cardiol 2024; 31:218-227. [PMID: 37767960 DOI: 10.1093/eurjpc/zwad314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 09/11/2023] [Accepted: 09/21/2023] [Indexed: 09/29/2023]
Abstract
AIMS Multiple health administrative databases can be individually linked in Aotearoa New Zealand, using encrypted identifiers. These databases were used to develop cardiovascular risk prediction equations for patients with known cardiovascular disease (CVD). METHODS AND RESULTS Administrative health databases were linked to identify all people aged 18-84 years with known CVD, living in Auckland and Northland, Aotearoa New Zealand, on 1 January 2014. The cohort was followed until study outcome, death, or 5 years. The study outcome was death or hospitalization due to ischaemic heart disease, stroke, heart failure, or peripheral vascular disease. Sex-specific 5-year CVD risk prediction equations were developed using multivariable Fine and Gray models. A total of 43 862 men {median age: 67 years [interquartile range (IQR): 59-75]} and 32 724 women [median age: 70 years (IQR: 60-77)] had 14 252 and 9551 cardiovascular events, respectively. Equations were well calibrated with good discrimination. Increasing age and deprivation, recent cardiovascular hospitalization, Mori ethnicity, smoking history, heart failure, diabetes, chronic renal disease, atrial fibrillation, use of blood pressure lowering and anti-thrombotic drugs, haemoglobin A1c, total cholesterol/HDL cholesterol, and creatinine were statistically significant independent predictors of the study outcome. Fourteen per cent of men and 23% of women had predicted 5-year cardiovascular risk <15%, while 28 and 24% had ≥40% risk. CONCLUSION Robust cardiovascular risk prediction equations were developed from linked routine health databases, a currently underutilized resource worldwide. The marked heterogeneity demonstrated in predicted risk suggests that preventive therapy in people with known CVD would be better informed by risk stratification beyond a one-size-fits-all high-risk categorization.
Collapse
Affiliation(s)
- Anders Holt
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
- Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Gentofte Hospitalsvej 6, Hellerup DK-2900, Denmark
| | - Bruno Batinica
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Jingyuan Liang
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Andrew Kerr
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
- Department of Medicine, School of Medicine, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
- Department of Cardiology, Middlemore Hospital, 100 Hospital Road, Otahuhu, Auckland 2025, New Zealand
| | - Sue Crengle
- Ngi Tahu Mori Health Research Unit, Division of Health Sciences, University of Otago, 362 Leith Street, Dunedin 9016, New Zealand
| | - Ben Hudson
- Department of Primary Care and Clinical Simulation, University of Otago, 2 Riccarton Avenue, Christchurch 8140, New Zealand
| | - Susan Wells
- Department of General Practice and Primary Health Care, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Matire Harwood
- Department of General Practice and Primary Health Care, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Suneela Mehta
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Corina Grey
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Morten Lamberts
- Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Gentofte Hospitalsvej 6, Hellerup DK-2900, Denmark
| | - Rod Jackson
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| | - Katrina K Poppe
- Department of Medicine, School of Medicine, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand
| |
Collapse
|
3
|
Newport R, Grey C, Dicker B, Brewer K, Amertunga S, Selak V, Hanchard S, Taueetia-Su'a T, Harwood M. Upholding te mana o te wā: Māori patients and their families' experiences of accessing care following an out-of-hospital cardiac event. Am Heart J Plus 2023; 36:100341. [PMID: 38510103 PMCID: PMC10945954 DOI: 10.1016/j.ahjo.2023.100341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 10/26/2023] [Accepted: 10/27/2023] [Indexed: 03/22/2024]
Abstract
Objective The purpose of this study was to explore the experiences of Māori patients and their families accessing care for an acute out-of-hospital cardiac event and to identify any barriers or enablers of timely access to care. Design Eleven interviews with patients and their families were conducted either face-to-face or using online conferencing. Interviews were audio-recorded and transcribed for thematic analysis using Kaupapa Māori methodology. Results Data analysis identified three themes: (1) me and the event, (2) the people (3) upholding te mana ō te wā or self-determined heart wellbeing. Knowledge of symptoms and a desire to maintain personal dignity at the time of the event affected emergency medical service initiation. Participants described relationships with health professionals, the importance of good quality information, having family support, and drawing on cultural practices as vital for their health care journey. Conclusion Systemic barriers including racism, discrimination, and inadequate resourcing exist for Māori journeying to and through care following an out of hospital cardiac event. Improving the cultural safety of health professionals, better access to community defibrillation, and improving understanding of the life-long impacts a cardiac event has on patients and whānau is recommended.
Collapse
Affiliation(s)
- Rochelle Newport
- Department of General Practice and Primary Health Care, The University of Auckland Faculty of Medical and Health Sciences, Private Bag 92019, Auckland 1142, New Zealand
| | - Corina Grey
- Te Whatu Ora |Health New Zealand - Counties Manukau, Auckland, New Zealand
| | - Bridget Dicker
- Hato Hone St John NZ & Auckland University of Technology Faculty of Health and Environmental Sciences, Auckland, New Zealand
| | - Karen Brewer
- The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
| | - Shanthi Amertunga
- The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
| | - Vanessa Selak
- The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
| | - Sandra Hanchard
- The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
| | - Tua Taueetia-Su'a
- The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
| | - Matire Harwood
- The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
| |
Collapse
|
4
|
Winter-Smith J, Grey C, Paynter J, Harwood M, Selak V. Who are Pacific peoples in terms of ethnicity and country of birth? A cross sectional study of 2,238,039 adults in Aotearoa New Zealand's Integrated Data Infrastructure. Dialogues Health 2023; 3:100152. [PMID: 38515801 PMCID: PMC10953968 DOI: 10.1016/j.dialog.2023.100152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 08/04/2023] [Accepted: 08/24/2023] [Indexed: 03/23/2024]
Abstract
Background The aggregation of Indigenous peoples from Pacific Island nations as 'Pacific peoples' in literature may mask diversity in the health needs of these different groups. The aim of this study was to examine the heterogeneity of Pacific groups according to ethnicity and country of birth. Methods Anonymised individual-level linkage of administrative data identified all NZ residents aged 30-74 years on 31 March 2013 with known ethnicity and country of birth. All participants were described according to ethnicity and country of birth. Pacific participants were also described according to the number of ethnicities they identified. Findings A total of 2,238,039 NZ residents were included, of whom 117,957 (5·0%) were Pacific. Nearly two-thirds of Pacific peoples (65·7%) were born overseas, ranging from 45·3% (Cook Islands Māori) to 82·7% (Fijian) (Māori 2·3%, non-Māori non-Pacific 28·9%). Among NZ-born Pacific peoples, 46·9% (Samoan) to 81·9% (Fijian) were multi-ethnic; the proportion was much lower for overseas-born Pacific peoples (ranging from 3·7% [Tongan] to 23·9% [Tokelauan]). Interpretation There is substantial heterogeneity among Pacific peoples in their country of birth and identification with sole or multiple ethnicities. Assumptions regarding homogeneity in the needs of Pacific peoples are not appropriate and government statistics should therefore disaggregate Pacific peoples whenever possible. Funding Supported by the Health Research Council of New Zealand and a part of Manawataki Fatu Fatu, a programme of research funded by the National Heart Foundation of New Zealand and Healthier Lives - He Oranga Hauora - National Science Challenge of New Zealand.
Collapse
Affiliation(s)
- Julie Winter-Smith
- Section of Epidemiology and Biostatistics, School of Population Health, The University of Auckland, Auckland, New Zealand
| | - Corina Grey
- Department of General Practice and Primary Healthcare, School of Population Health, The University of Auckland, Auckland, New Zealand
| | - Janine Paynter
- Department of General Practice and Primary Healthcare, School of Population Health, The University of Auckland, Auckland, New Zealand
| | - Matire Harwood
- Department of General Practice and Primary Healthcare, School of Population Health, The University of Auckland, Auckland, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, School of Population Health, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
5
|
Kerr AJ, Choi Y, Williams MJ, Stewart RA, White HD, Devlin G, Selak V, Lee MAW, El-Jack S, Adamson PD, Fairley S, Jackson RT, Poppe K. Paired risk scores to predict ischaemic and bleeding risk twenty-eight days to one year after an acute coronary syndrome. Heart 2023; 109:1827-1836. [PMID: 37558394 DOI: 10.1136/heartjnl-2023-322830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Accepted: 07/03/2023] [Indexed: 08/11/2023] Open
Abstract
OBJECTIVE The recommended duration of dual anti-platelet therapy (DAPT) following acute coronary syndrome (ACS) varies from 1 month to 1 year depending on the balance of risks of ischaemia and major bleeding. We designed paired ischaemic and major bleeding risk scores to inform this decision. METHODS New Zealand (NZ) patients with ACS investigated with coronary angiography are recorded in the All NZ ACS Quality Improvement registry and linked to national health datasets. Patients were aged 18-84 years (2012-2020), event free at 28 days postdischarge and without atrial fibrillation. Two 28-day to 1-year postdischarge multivariable risk prediction scores were developed: (1) cardiovascular mortality/rehospitalisation with myocardial infarction or ischaemic stroke (ischaemic score) and (2) bleeding mortality/rehospitalisation with bleeding (bleeding score). FINDINGS In 27 755 patients, there were 1200 (4.3%) ischaemic and 548 (2.0%) major bleeding events. Both scores were well calibrated with moderate discrimination performance (Harrell's c-statistic 0.75 (95% CI, 0.74 to 0.77) and 0.69 (95% CI, 0.67 to 0 .71), respectively). Applying these scores to the 2020 European Society of Cardiology ACS antithrombotic treatment algorithm, the 31% of the cohort at elevated (>2%) bleeding and ischaemic risk would be considered for an abbreviated DAPT duration. For those at low bleeding risk, but elevated ischaemic risk (37% of the cohort), prolonged DAPT may be appropriate, and for those with low bleeding and ischaemic risk (29% of the cohort) short duration DAPT may be justified. CONCLUSION We present a pair of ischaemic and bleeding risk scores specifically to assist clinicians and their patients in deciding on DAPT duration beyond the first month post-ACS.
Collapse
Affiliation(s)
- Andrew J Kerr
- Department of Medicine, The University of Auckland, Auckland, New Zealand
- Cardiology Department, Middlemore Hospital, Auckland, New Zealand
- Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| | - Yeunhyang Choi
- Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| | | | - Ralph Ah Stewart
- Cardiology Department, Greenlane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
| | - Harvey D White
- Cardiology Department, Greenlane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
| | | | - Vanessa Selak
- Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| | | | | | - Philip D Adamson
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
- Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK
| | - Sarah Fairley
- Cardiology Department, Wellington Hospital, Wellington, New Zealand
| | - Rodney T Jackson
- Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| | - Katrina Poppe
- Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
6
|
Tawfiq E, Pylypchuk R, Elwood JM, McKeage M, Wells S, Selak V. Risk of cardiovascular disease in cancer survivors: A cohort study of 446,384 New Zealand primary care patients. Cancer Med 2023; 12:20081-20093. [PMID: 37746882 PMCID: PMC10587917 DOI: 10.1002/cam4.6580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 08/11/2023] [Accepted: 09/12/2023] [Indexed: 09/26/2023] Open
Abstract
BACKGROUND Given advances in the management of cancer, it is increasingly important for clinicians to appropriately manage the risk of cardiovascular disease (CVD) among cancer survivors. It is unclear whether CVD risk is increased among cancer survivors overall, and there is inconsistency in evidence to date about CVD incidence and mortality by cancer type. METHODS Patients aged 30-74 years entered an open cohort study at the time of first CVD risk assessment, between 2004 and 2018, in primary care in New Zealand. Patients with established CVD or cancer within 2 years prior to study entry were excluded. Cancer diagnosis (1995-2016) was determined from a national cancer registry. Cause-specific hazard models were used to examine the association between history of cancer and two outcomes: (1) CVD-related hospitalization and/or death and (2) CVD death. RESULTS The study included 446,384 patients, of whom 14,263 (3.2%) were cancer survivors. Risk of CVD hospitalization and/or death was increased among cancer survivors compared with patients without cancer at cohort entry (multivariable-adjusted hazard ratio, mHR, 1.11, 95% CI 1.05-1.18), more so for CVD death (1.31, 1.14-1.52). Risk of CVD hospitalization and/or death was increased in patients with myeloma (2.66, 1.60-4.42), lung cancer (2.19, 1.48-3.24) and non-Hodgkin lymphoma (1.90, 1.42-2.54), but not for some cancers (e.g., colorectal, 0.87, 0.71-1.06). Risk of CVD death was increased in several cancer types including melanoma (1.73, 1.25-2.38) and breast cancer (1.56, 1.16-2.11). CONCLUSION CVD risk management needs to be prioritized among cancer survivors overall, and particularly in those with myeloma, lung cancer and non-Hodgkin lymphoma given consistent evidence of increased risk.
Collapse
Affiliation(s)
- Essa Tawfiq
- School of Population HealthUniversity of AucklandAucklandNew Zealand
| | - Romana Pylypchuk
- School of Population HealthUniversity of AucklandAucklandNew Zealand
| | - J. Mark Elwood
- School of Population HealthUniversity of AucklandAucklandNew Zealand
| | - Mark McKeage
- School of Medical SciencesUniversity of AucklandAucklandNew Zealand
| | - Sue Wells
- School of Population HealthUniversity of AucklandAucklandNew Zealand
| | - Vanessa Selak
- School of Population HealthUniversity of AucklandAucklandNew Zealand
| |
Collapse
|
7
|
Yang CJ, Selak V, Schaaf D, Nosa V. Pacific patients' reasons for attending the emergency department of Counties Manukau for non-urgent conditions. N Z Med J 2023; 136:22-34. [PMID: 37778317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/03/2023]
Abstract
AIM To determine Pacific patients' reasons for Emergency Department (ED) use for non-urgent conditions by Pacific people at Counties Manukau Health. METHODS Patients who self-presented to Counties Manukau ED with a non-urgent condition in June 2019 were surveyed. Responses to open-ended questions were analysed using a general inductive approach, in discussion with key stakeholders. RESULTS Of 353 participants with ethnicity reported, 139 (39%) were Pacific, 66 (19%) Māori and 148 (42%) were non-Māori non-Pacific, nMnP. A total of 58 (42%) of Pacific participants had been to their general practitioner prior to presenting to the ED; this proportion was similar for Māori (19 [30%]) and nMnP (59 [40%]) (p=0.215). The most common reasons for ED attendance among Pacific (as well as other) participants were 1) advice by a health professional (41%, 95% CI 33-50%), 2) usual care unavailable (28%, 20-36%), 3) symptoms not improving (21%, 14-28%), and 4) symptoms too severe to be managed elsewhere (19%, 12-26%). CONCLUSIONS Multiple reasons underlie non-urgent use of EDs by Pacific and other ethnic groups. These reasons need to be considered simultaneously in the design, implementation, and evaluation of multi-dimensional initiatives that discourage non-urgent use of EDs to ensure that such initiatives are effective, equitable, and unintended consequences are avoided.
Collapse
Affiliation(s)
- Catherine J Yang
- Public Health Registrar, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland
| | - Vanessa Selak
- Senior Lecturer, Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland
| | - David Schaaf
- Principal Advisor Pacific, Te Aho o Te Kahu Cancer Control Agency
| | - Vili Nosa
- Associate Professor, Pacific Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland
| |
Collapse
|
8
|
Mellar BM, Hashemi L, Selak V, Gulliver PJ, McIntosh TK, Fanslow JL. Association Between Women's Exposure to Intimate Partner Violence and Self-reported Health Outcomes in New Zealand. JAMA Netw Open 2023; 6:e231311. [PMID: 36867408 PMCID: PMC9984970 DOI: 10.1001/jamanetworkopen.2023.1311] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/04/2023] Open
Abstract
IMPORTANCE Intimate partner violence (IPV) is increasingly recognized as a contributing factor for long-term health problems; however, few studies have assessed these health outcomes using consistent and comprehensive IPV measures or representative population-based samples. OBJECTIVE To examine associations between women's lifetime IPV exposure and self-reported health outcomes. DESIGN, SETTING, AND PARTICIPANTS The cross-sectional, retrospective 2019 New Zealand Family Violence Study, adapted from the World Health Organization's Multi-Country Study on Violence Against Women, assessed data from 1431 ever-partnered women (63.7% of eligible women contacted) in New Zealand. The survey was conducted from March 2017 to March 2019, across 3 regions, which accounted for approximately 40% of the New Zealand population. Data analysis was performed from March to June 2022. EXPOSURES Exposures were lifetime IPV by types (physical [severe/any], sexual, psychological, controlling behaviors, and economic abuse), any IPV (at least 1 type), and number of IPV types. MAIN OUTCOMES AND MEASURES Outcome measures were poor general health, recent pain or discomfort, recent pain medication use, frequent pain medication use, recent health care consultation, any diagnosed physical health condition, and any diagnosed mental health condition. Weighted proportions were used to describe the prevalence of IPV by sociodemographic characteristics; bivariate and multivariable logistic regressions were used for the odds of experiencing health outcomes by IPV exposure. RESULTS The sample comprised 1431 ever-partnered women (mean [SD] age, 52.2 [17.1] years). The sample was closely comparable with New Zealand's ethnic and area deprivation composition, although younger women were slightly underrepresented. More than half of the women (54.7%) reported any lifetime IPV exposure, of whom 58.8% experienced 2 or more IPV types. Compared with all other sociodemographic subgroups, women who reported food insecurity had the highest IPV prevalence for any IPV (69.9%) and all specific types. Exposure to any IPV and specific IPV types was significantly associated with increased likelihood of reporting adverse health outcomes. Compared with those unexposed to IPV, women who experienced any IPV were more likely to report poor general health (adjusted odds ratio [AOR], 2.02; 95% CI, 1.46-2.78), recent pain or discomfort (AOR, 1.81; 95% CI, 1.34-2.46), recent health care consultation (AOR, 1.29; 95% CI, 1.01-1.65), any diagnosed physical health condition (AOR, 1.49; 95% CI, 1.13-1.96), and any mental health condition (AOR, 2.78; 95% CI, 2.05-3.77). Findings suggested a cumulative or dose-response association because women who experienced multiple IPV types were more likely to report poorer health outcomes. CONCLUSIONS AND RELEVANCE In this cross-sectional study of women in New Zealand, IPV exposure was prevalent and associated with an increased likelihood of experiencing adverse health. Health care systems need to be mobilized to address IPV as a priority health issue.
Collapse
Affiliation(s)
- Brooklyn M. Mellar
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Ladan Hashemi
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
- Violence and Society Centre, School of Policy and Global Affairs, City University of London, London, United Kingdom
| | - Vanessa Selak
- Department of Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Pauline J. Gulliver
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Tracey K.D. McIntosh
- School of Māori Studies and Pacific Studies, Faculty of Arts, The University of Auckland, Auckland, New Zealand
| | - Janet L. Fanslow
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
9
|
Tawfiq E, Selak V, Elwood JM, Pylypchuk R, Tin ST, Harwood M, Grey C, McKeage M, Wells S. Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study. Lancet 2023; 401:357-365. [PMID: 36702148 DOI: 10.1016/s0140-6736(22)02405-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 09/04/2022] [Accepted: 11/17/2022] [Indexed: 01/25/2023]
Abstract
BACKGROUND People with cancer have an increased risk of cardiovascular disease. Risk prediction equations developed in New Zealand accurately predict 5-year cardiovascular disease risk in a general primary care population in the country. We assessed the performance of these equations for survivors of cancer in New Zealand. METHODS For this validation study, patients aged 30-74 years from the PREDICT open cohort study, which was used to develop the New Zealand cardiovascular disease risk prediction equations, were included in the analysis if they had a primary diagnosis of invasive cancer at least 2 years before the date of the first cardiovascular disease risk assessment. The risk prediction equations are sex-specific and include the following predictors: age, ethnicity, socioeconomic deprivation index, family history of cardiovascular disease, smoking status, history of atrial fibrillation and diabetes, systolic blood pressure, total cholesterol to HDL cholesterol ratio, and preventive pharmacotherapy (blood-pressure-lowering, lipid-lowering, and antithrombotic drugs). Calibration was assessed by comparing the mean predicted 5-year cardiovascular disease risk, estimated using the risk prediction equations, with the observed risk across deciles of risk, for men and women, and according to the three clinical 5-year cardiovascular disease risk groups in New Zealand guidelines (<5%, 5% to <15%, and ≥15%). Discrimination was assessed by Harrell's C statistic. FINDINGS 14 263 patients were included in the study. The mean age was 61 years (SD 9) for men and 60 years (SD 8) for women, with a median follow-up of 5·8 years for men and 5·7 years for women. The observed cardiovascular disease risk was underpredicted by a maximum of 2·5% in male and 3·2% in female decile groups. When patients were grouped according to clinical risk groups, observed cardiovascular disease risk was underpredicted by less than 2% in the lower risk groups and overpredicted by 2·2% for men and 3·3% for women in the highest risk group. Harrell's C statistics were 0·67 (SE 0·01) for men and 0·73 (0·01) for women. INTERPRETATION The New Zealand cardiovascular disease risk prediction equations reasonably predicted the observed 5-year cardiovascular disease risk in survivors of cancer in the country, in whom risk prediction was considered clinically appropriate. Prediction could be improved by adding cancer-specific variables and considering competing risks. Our findings suggest that the equations are reasonable clinical tools for use in survivors of cancer in New Zealand. FUNDING Auckland Medical Research Foundation, Health Research Council of New Zealand.
Collapse
Affiliation(s)
- Essa Tawfiq
- School of Population Health, University of Auckland, Auckland, New Zealand.
| | - Vanessa Selak
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - J Mark Elwood
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - Romana Pylypchuk
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - Sandar Tin Tin
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - Matire Harwood
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - Corina Grey
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - Mark McKeage
- School of Medical Sciences, University of Auckland, Auckland, New Zealand
| | - Sue Wells
- School of Population Health, University of Auckland, Auckland, New Zealand
| |
Collapse
|
10
|
Mellar BM, Gulliver PJ, Selak V, Hashemi L, McIntosh TKD, Fanslow JL. Association Between Men's Exposure to Intimate Partner Violence and Self-reported Health Outcomes in New Zealand. JAMA Netw Open 2023; 6:e2252578. [PMID: 36696112 PMCID: PMC10187486 DOI: 10.1001/jamanetworkopen.2022.52578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 11/29/2022] [Indexed: 01/26/2023] Open
Abstract
Importance Health implications of intimate partner violence (IPV) against men is relatively underexplored, although substantial evidence has identified associations between IPV and long-term physical health problems for women. Given the gendered differences in IPV exposure patterns, exploration of men's IPV exposure and health outcomes using population-based samples is needed. Objective To assess the association between men's lifetime IPV exposure and self-reported health outcomes. Design, Setting, and Participants This cross-sectional study analyzed data from the 2019 New Zealand Family Violence Study, which was conducted across 3 regions of New Zealand. The representative sample included ever-partnered men aged 16 years or older. Data analysis was performed between May and September 2022. Exposures Lifetime IPV against men by types (physical [severe or any], sexual, psychological, controlling behaviors, and economic abuse), any IPV (at least 1 type), and number of IPV types experienced. Main Outcomes and Measures The 7 health outcomes were poor general health, recent pain or discomfort, recent use of pain medication, frequent use of pain medication, recent health care consultation, any diagnosed physical health condition, and any diagnosed mental health condition. Results The sample comprised 1355 ever-partnered men (mean [SD] age, 51.3 [16.9] years), who predominantly identified as heterosexual (96.9%; 95% CI, 95.7%-97.8%). Half of the sample (49.9%) reported experiencing any lifetime IPV, of whom 62.1% reported at least 2 types. Of all sociodemographic subgroups, unemployed men had the greatest prevalence of reporting exposure to any IPV (69.2%) and all IPV types. After adjustment for sociodemographic factors, men's exposure to any lifetime IPV was associated with an increased likelihood of reporting 4 of the 7 assessed health outcomes: poor general health (adjusted odds ratio [AOR], 1.78; 95% CI, 1.34-2.38), recent pain or discomfort (AOR, 1.65; 95% CI, 1.21-2.25), recent use of pain medication (AOR, 1.27; 95% CI, 1.00-1.62), and any diagnosed mental health condition (AOR, 1.66; 95% CI, 1.11-2.49). Specific IPV types were inconsistently associated with poor health outcomes. Any physical IPV exposure was associated with poor general health (AOR, 1.80; 95% CI, 1.33-2.43), recent pain or discomfort (AOR, 2.23; 95% CI, 1.64-3.04), and frequent use of pain medication (AOR, 1.69; 95% CI, 1.08-2.63), which appeared to be associated with exposure to severe physical IPV. Exposure to sexual IPV, controlling behaviors, and economic abuse was not associated with any assessed outcomes after sociodemographic adjustment. Experience of a higher number of IPV types did not show a clear stepwise association with number of health outcomes. Conclusions and Relevance Results of this study indicate that exposure to IPV can adversely affect men's health but is not consistently a factor in men's poor health at the population level. These findings do not warrant routine inquiry for IPV against men in clinical settings, although appropriate care is needed if IPV against men is identified.
Collapse
Affiliation(s)
- Brooklyn M. Mellar
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Pauline J. Gulliver
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Vanessa Selak
- Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Ladan Hashemi
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
- Violence and Society Centre, School of Policy and Global Affairs, City, University of London, London, United Kingdom
| | - Tracey K. D. McIntosh
- School of Māori Studies and Pacific Studies, Faculty of Arts, The University of Auckland, Auckland, New Zealand
| | - Janet L. Fanslow
- School of Social and Community Health, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
11
|
Gnanenthiran SR, Webster R, Silva AD, Maulik PK, Salam A, Selak V, Guggilla RK, Schutte AE, Patel A, Rodgers A. Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitus-results from the TRIUMPH randomised controlled trial. Hypertens Res 2023; 46:128-135. [PMID: 36229537 DOI: 10.1038/s41440-022-01051-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 09/08/2022] [Accepted: 09/19/2022] [Indexed: 02/03/2023]
Abstract
We investigated whether diabetes mellitus (DM) affects the efficacy of a low-dose triple combination pill and usual care among people with mild-moderate hypertension. TRIUMPH (TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension) was a randomised controlled open-label trial of patients requiring initiation or escalation of antihypertensive therapy. Patients were randomised to a once-daily low-dose triple combination polypill (telmisartan-20mg/amlodipine-2.5 mg/chlorthalidone-12.5 mg) or usual care. This analysis compared BP reduction in people with and without DM, both in the intervention and control groups over 24-week follow-up. Predicted efficacy of prescribed therapy was calculated (estimation methods of Law et al.). The trial randomised 700 patients (56 ± 11 yrs, 31% DM). There was no difference in the number of drugs prescribed or predicted efficacy of therapy between people with DM and without DM. However, the observed BP reduction from baseline to week 24 was lower in those with DM compared to non-diabetics in both the triple pill (25/11 vs 31/15 mmHg, p ≤ 0.01) and usual care (17/7 vs 22/11 mmHg, p ≤ 0.01) groups, and these differences remained after multivariable adjustment. DM was a negative predictor of change in BP (β-coefficient -0.08, p = 0.02). In conclusion, patients with DM experienced reduced efficacy of BP lowering therapies as compared to patients without DM, irrespective of the type of BP lowering therapy received.
Collapse
Affiliation(s)
- Sonali R Gnanenthiran
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| | - Ruth Webster
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
- School of Population Health, UNSW, Sydney, Australia
| | - Asita de Silva
- Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
| | | | - Abdul Salam
- The George Institute for Global Health, Hyderabad, India
| | - Vanessa Selak
- Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Rama K Guggilla
- Department of Population Medicine and Lifestyle Diseases Prevention, Faculty of Medicine with the Division of Dentistry and Division of Medical Education in English, Medical University of Bialystok, Bialystok, Poland
| | - Aletta E Schutte
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| | - Anushka Patel
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| | - Anthony Rodgers
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
| |
Collapse
|
12
|
Tane T, Selak V, Eggleton K, Harwood M. Understanding the barriers and facilitators that influence access to quality cardiovascular care for rural Indigenous peoples: protocol for a scoping review. BMJ Open 2022; 12:e065685. [PMID: 36523251 PMCID: PMC9748974 DOI: 10.1136/bmjopen-2022-065685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
INTRODUCTION Māori (the Indigenous peoples of New Zealand) are disproportionately represented in cardiovascular disease (CVD) prevalence, morbidity and mortality rates, and are less likely to receive evidence-based CVD healthcare. Rural Māori experience additional barriers to treatment access, poorer health outcomes and a more significant burden of CVD risk factors compared with non-Māori and Māori living in urban areas. Importantly, these inequities are similarly experienced by Indigenous peoples in other nations impacted by colonisation. Given the scarcity of available literature, we are conducting a scoping review of literature exploring barriers and facilitators in accessing quality CVD healthcare for rural Māori and other Indigenous peoples in nations impacted by colonisation. METHODS AND ANALYSIS A scoping review will be conducted to identify and map the extent of research available and identify any gaps in the literature. This review will be underpinned by Kaupapa Māori Research methodology and will be conducted using Arksey and O'Malley's (2005) methodological framework. A database search of MEDLINE (OVID), PubMed, Embase, SCOPUS, CINAHL Plus, Australia/New Zealand Reference Centre and NZResearch.org will be used to explore empirical research literature. A grey literature search will also be conducted. Two authors will independently review and screen search results in an iterative manner. The New Zealand Ministry of Health Te Tiriti o Waitangi (Treaty of Waitangi) Framework principles will be used as a framework to summarise and construct a narrative of existing literature. Existing literature will also be appraised using the CONSolIDated critERia for strengthening the reporting of health research involving Indigenous Peoples (CONSIDER) statement. ETHICS AND DISSEMINATION Ethical approval has not been sought for this review as we are using publicly available data. We will publish this protocol and the findings of our review in an open-access peer-reviewed journal. This protocol has been registered on Open Science Framework (DOI:10.17605/osf.io/xruhy).
Collapse
Affiliation(s)
- Taria Tane
- Department of General Practice and Primary Health Care, The University of Auckland, Auckland, New Zealand
| | - Vanessa Selak
- Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| | - Kyle Eggleton
- Department of General Practice and Primary Health Care, The University of Auckland, Auckland, New Zealand
| | - Matire Harwood
- Department of General Practice and Primary Health Care, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
13
|
Selak V, Poppe K, Chan D, Grey C, Harwood M, Ameratunga S, Hanchard S, Wells S, Kerr A, Lund M, Doughty R. Identification of clinically relevant cohorts of people with heart failure from electronic health data in Aotearoa: potential, pitfalls and a plan. N Z Med J 2022; 135:96-104. [PMID: 36201734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Heart failure (HF) is associated with high morbidity and mortality and contributes to substantial burden of disease, significant inequities and high healthcare cost globally as well as in Aotearoa. Management of chronic HF is driven by HF phenotype, defined by left ventricular ejection fraction (EF), as only those with reduced ejection fraction (HFrEF) have been shown to experience reduced mortality and morbidity with long-term pharmacotherapy. To ensure appropriate and equitable implementation of HF management we need to be able to identify clinically relevant cohorts of patients with HF, in particular, those with HFrEF. The ideal HF registry would incorporate and link HF diagnoses and phenotype from primary and secondary care with echocardiography and pharmacotherapy data. In this article we consider several options for identifying such cohorts from electronic health data in Aotearoa, as well as the potential and pitfalls of these options. Given the urgent need to identify people with HF according to EF phenotype, the options for identifying them from electronic health data, and the opportunities presented by health system reform, including a focus on digital solutions, we recommend the following four actions, with oversight from a national HF working group: 1) Establish a HF registry based on random and representative sampling of HF admissions; 2) investigate obtaining HF diagnosis and EF-phenotype from primary care-coded data; 3) amalgamate national echocardiography data; and 4) investigate options to enable the systematic collection of HF diagnosis and EF-phenotype from outpatient attendances. Future work will need to consider reliability and concordance of data across sources. The case for urgent action in Aotearoa is compounded by the stark inequities in the burden of HF, the likely contribution of health service factors to these inequities and the legislative requirement under the Pae Ora (Healthy Futures) Act 2022 that "the health sector should be equitable, which includes ensuring Māori and other population groups - (i) have access to services in proportion to their health needs; and (ii) receive equitable levels of service; and (iii) achieve equitable health outcomes".
Collapse
Affiliation(s)
- Vanessa Selak
- School of Population Health, The University of Auckland, New Zealand
| | - Katrina Poppe
- Department of Medicine, The University of Auckland, New Zealand
| | | | - Corina Grey
- Section of Epidemiology and Biostatistics, The University of Auckland, New Zealand
| | - Matire Harwood
- General Practice and Primary Care, The University of Auckland, New Zealand
| | - Shanthi Ameratunga
- Section of Epidemiology & Biostatistics School of Population Health, Faculty of Medical & Health Sciences, The University of Auckland, New Zealand
| | - Sandra Hanchard
- General Practice and Primary Care, The University of Auckland, New Zealand
| | - Sue Wells
- Section of Epidemiology and Biostatistics School of Population Health, The University of Auckland
| | - Andrew Kerr
- Cardiology Dept Middlemore Hospital, New Zealand
| | - Mayanna Lund
- Cardiology Dept Middlemore Hospital, New Zealand
| | - Rob Doughty
- Medicine, The University of Auckland, New Zealand
| |
Collapse
|
14
|
Brewer KM, Grey C, Paynter J, Winter-Smith J, Hanchard S, Selak V, Ameratunga S, Harwood M. What are the gaps in cardiovascular risk assessment and management in primary care for Māori and Pacific people in Aotearoa New Zealand? Protocol for a systematic review. BMJ Open 2022; 12:e060145. [PMID: 35676004 PMCID: PMC9185566 DOI: 10.1136/bmjopen-2021-060145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
INTRODUCTION In New Zealand, significant inequities exist between Māori and Pacific peoples compared with non-Māori, non-Pacific peoples in cardiovascular disease (CVD) risk factors, hospitalisations and management rates. This review will quantify and qualify already-reported gaps in CVD risk assessment and management in primary care for Māori and Pacific peoples compared with non-Māori/non-Pacific peoples in New Zealand. METHODS AND ANALYSIS We will conduct a systematic search of the following electronic databases and websites from 1 January 2000 to 31 December 2021: MEDLINE (OVID), EMBASE, Scopus, CINAHL Plus, NZresearch.org, National Library Catalogue (Te Puna), Index New Zealand (INNZ), Australia/New Zealand Reference Centre. In addition, we will search relevant websites such as the Ministry of Health and research organisations. Data sources will include published peer reviewed articles, reports and theses employing qualitative, quantitative and mixed methods.Two reviewers will independently screen the titles and abstracts of the citations and grade each as eligible, not eligible or might be eligible. Two reviewers will read each full report, with one medically qualified reviewer reading all reports and two other reviewers reading half each. The final list of included citations will be compiled from the results of the full report reading and agreed on by three reviewers. Data abstracted will include authors, title, year, study characteristics and participant characteristics. Data analysis and interpretation will involve critical inquiry and a strength-based approach that is inclusive of Māori and Pacific values. This means that critical appraisal includes an assessment of quality from an Indigenous perspective. ETHICS AND DISSEMINATION Ethical approval is not required. The findings will be published in a peer-reviewed journal and shared with stakeholders. This review contributes to a larger project which creates a Quality-Improvement Equity Roadmap to reduce barriers to Māori and Pacific peoples accessing evidence-based CVD care.
Collapse
Affiliation(s)
- Karen Marie Brewer
- Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Corina Grey
- Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Janine Paynter
- Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Julie Winter-Smith
- Section of Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Sandra Hanchard
- Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Shanthi Ameratunga
- Section of Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
- Population Health Directorate, Counties Manukau Health, Auckland, New Zealand
| | - Matire Harwood
- Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
15
|
Win Myint TT, Selak V, Elwood M. The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand). Skin Health and Disease 2022; 3:e116. [PMID: 37013115 PMCID: PMC10066759 DOI: 10.1002/ski2.116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 03/21/2022] [Accepted: 03/22/2022] [Indexed: 11/07/2022]
Abstract
Background Patients with invasive melanoma are at increased risk of developing subsequent invasive melanoma, but the risks for those with primary in situ melanoma are unclear. Objectives To assess and compare the cumulative risk of subsequent invasive melanoma after primary invasive or in situ melanoma. To estimate the standardized incidence ratio (SIR) of subsequent invasive melanoma compared to population incidence in both cohorts. Methods Patients with a first diagnosis of melanoma (invasive or in situ) between 2001 and 2017 were identified from the New Zealand national cancer registry, and any subsequent invasive melanoma during follow-up to the end of 2017 identified. Cumulative risk of subsequent invasive melanoma was estimated by Kaplan-Meier analysis separately for primary invasive and in situ cohorts. Risk of subsequent invasive melanoma was assessed using Cox proportional hazard models. SIR was assessed, allowing for age, sex, ethnicity, year of diagnosis and follow up time. Results Among 33 284 primary invasive and 27 978 primary in situ melanoma patients, median follow up time was 5.5 and 5.7 years, respectively. A subsequent invasive melanoma developed in 1777 (5%) of the invasive and 1469 (5%) of the in situ cohort, with the same median interval (2.5 years) from initial to first subsequent lesion in both cohorts. The cumulative incidence of subsequent invasive melanoma at 5 years was similar in the two cohorts (invasive 4.2%, in situ 3.8%); the cumulative incidence increased linearly over time in both cohorts. The risk of subsequent invasive melanoma was marginally higher for primary invasive compared to in situ melanoma after adjustment for age, sex, ethnicity and body site of the initial lesion (hazard ratio 1.11, 95% CI 1.02-1.21). Compared to population incidence, the SIR of invasive melanoma was 4.6 (95% CI 4.3-4.9) for the primary invasive and 4 (95% CI 3.7-4.2) for the primary in situ melanoma cohorts. Conclusions The risk of subsequent invasive melanoma is similar whether patients present with in situ or invasive melanoma. Thus follow-up surveillance for new lesions should be similar, although patients with invasive melanoma require more surveillance for recurrence.
Collapse
Affiliation(s)
- Thu Thu Win Myint
- Department of Biostatistics and Epidemiology University of Auckland Auckland New Zealand
| | - Vanessa Selak
- Department of Biostatistics and Epidemiology University of Auckland Auckland New Zealand
| | - Mark Elwood
- Department of Biostatistics and Epidemiology University of Auckland Auckland New Zealand
| |
Collapse
|
16
|
Gnanenthiran SR, Wang N, Di Tanna GL, Salam A, Webster R, de Silva HA, Guggilla R, Jan S, Maulik PK, Naik N, Selak V, Thom S, Prabhakaran D, Schutte AE, Patel A, Rodgers A. Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial. JAMA Cardiol 2022; 7:645-650. [PMID: 35416909 PMCID: PMC9008553 DOI: 10.1001/jamacardio.2022.0471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Importance Cumulative exposure to high blood pressure (BP) is an adverse prognostic marker. Assessments of BP control over time, such as time at target, have been developed but assessments of the effects of BP-lowering interventions on such measures are lacking. Objective To evaluate whether low-dose triple combination antihypertensive therapy was associated with greater rates of time at target compared with usual care. Design, Setting, and Participants The Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension (TRIUMPH) trial was a open-label randomized clinical trial of low-dose triple BP therapy vs usual care conducted in urban hospital clinics in Sri Lanka from February 2016 to May 2017. Adults with hypertension (systolic BP >140 mm Hg and/or diastolic BP >90 mm Hg or in patients with diabetes or chronic kidney disease, systolic BP >130 mm Hg and/or diastolic BP >80 mm Hg) requiring initiation (untreated patients) or escalation (patients receiving monotherapy) of antihypertensive therapy were included. Patients were excluded if they were currently taking 2 or more blood pressure-lowering drugs or had severe or uncontrolled blood pressure, accelerated hypertension or physician-determined need for slower titration of treatment, a contraindication to the triple combination pill therapy, an unstable medical condition, or clinically significant laboratory values deemed by researchers to be unsuitable for the study. All 700 individuals in the original trial were included in the secondary analysis. This post hoc analysis was conducted from December 2020 to December 2021. Intervention Once-daily fixed-dose triple combination pill (telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg) therapy vs usual care. Main Outcomes and Measures Between-group differences in time at target were compared over 24 weeks of follow-up, with time at target defined as percentage of time at target BP. Results There were a total of 700 randomized patients (mean [SD] age, 56 [11] years; 403 [57.6%] women). Patients allocated to the triple pill group (n = 349) had higher time at target compared with those in the usual care group (n = 351) over 24 weeks' follow-up (64% vs 43%; risk difference, 21%; 95% CI, 16-26; P < .001). Almost twice as many patients receiving triple pill therapy achieved more than 50% time at target during follow-up (64% vs 37%; P < .001). The association of the triple pill with an increase in time at target was seen early, with most patients achieving more than 50% time at target by 12 weeks. Those receiving the triple pill achieved a consistently higher time at target at all follow-up periods compared with those receiving usual care (mean [SD]: 0-6 weeks, 36.3% [30.9%] vs 21.7% [28.9%]; P < .001; 6-12 weeks, 5.2% [31.9%] vs 33.7% [33.0%]; P < .001; 12-24 weeks, 66.0% [31.1%] vs 43.5% [34.3%]; P < .001). Conclusions and Relevance To our knowledge, this analysis provides the first estimate of time at target as an outcome assessing longitudinal BP control in a randomized clinical trial. Among patients with mild to moderate hypertension, treatment with a low-dose triple combination pill was associated with substantially higher time at target compared with usual care.
Collapse
Affiliation(s)
- Sonali R Gnanenthiran
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Nelson Wang
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Gian Luca Di Tanna
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Abdul Salam
- The George Institute for Global Health, Hyderabad, India University of New South Wales, Sydney, New South Wales, Australia
| | - Ruth Webster
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.,Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia
| | - H Asita de Silva
- Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
| | - Rama Guggilla
- Department of Population Medicine and Lifetsyle Diseases Prevention, Faculty of Medicine with the Division of Dentistry and Division of Medical Education in English, Medical University of Bialystok, Bialystok, Poland
| | - Stephen Jan
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Pallab K Maulik
- The George Institute for Global Health, Hyderabad, India University of New South Wales, Sydney, New South Wales, Australia
| | - Nitish Naik
- All India Institute of Medical Sciences, New Delhi
| | - Vanessa Selak
- Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Simon Thom
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Dorairaj Prabhakaran
- Centre for Chronic Disease Control and Public Health Foundation, New Delhi, India
| | - Aletta E Schutte
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Anushka Patel
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Anthony Rodgers
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | | |
Collapse
|
17
|
Broadbent N, Selak V. Sounding a note of caution: first trimester anaesthesia and congenital heart defects. Int J Epidemiol 2022; 51:746-748. [PMID: 35381079 DOI: 10.1093/ije/dyac065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 03/30/2022] [Indexed: 11/12/2022] Open
Affiliation(s)
- Nicola Broadbent
- Department of Anaesthesia and Perioperative Medicine, Auckland District Health Board, Auckland, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| |
Collapse
|
18
|
Wells S, Choi Y, Jackson R, Parwaiz M, Mehta S, Selak V, Harwood M, Grey C, Kerse N, Poppe K. Cardiovascular disease preventive medication dispensing for almost every New Zealander 65 years and over: a preventive treatment paradox? Age Ageing 2022; 51:6514237. [PMID: 35077560 DOI: 10.1093/ageing/afab265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 09/15/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE To describe the dispensing of cardiovascular disease (CVD) preventive medications among older New Zealanders with and without prior CVD or diabetes. METHODS New Zealanders aged ≥65 years in 2013 were identified using anonymised linkage of national administrative health databases. Dispensing of blood pressure lowering (BPL), lipid lowering (LL) or antithrombotic (AT) medications, was documented, stratified by age and by history of CVD, diabetes, or neither. RESULTS Of the 593,549 people identified, 32% had prior CVD, 14% had diabetes (of whom half also had prior CVD) and 61% had neither diagnosis. For those with prior CVD, between 79-87% were dispensed BPL and 73-79% were dispensed AT medications, across all age groups. In contrast, LL dispensing was lower than either BPL or AT in every age group, falling from 75% at age 65-69 years to 43% at 85+ years. For people with diabetes, BPL and LL dispensing was similar to those with prior CVD, but AT dispensing was approximately 20% lower. Among people without prior CVD or diabetes, both BPL and AT dispensing increased with age (from 39% and 17% at age 65-69 years to 56% and 35% at 85+ years respectively), whereas LL dispensing was 26-31% across the 65-84 year age groups, falling to 17% at 85+ years. CONCLUSION The much higher dispensing of BPL and AT compared to LL medications with increasing age suggests a preventive treatment paradox for older people, with the medications most likely to cause adverse effects being dispensed most often.
Collapse
|
19
|
Winter-Smith J, Selak V, Harwood M, Ameratunga S, Grey C. Cardiovascular disease and its management among Pacific people: a systematic review by ethnicity and place of birth. BMC Cardiovasc Disord 2021; 21:515. [PMID: 34689737 PMCID: PMC8543825 DOI: 10.1186/s12872-021-02313-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2021] [Accepted: 10/08/2021] [Indexed: 11/15/2022] Open
Abstract
Background Pacific people experience a disproportionate burden of cardiovascular disease (CVD), whether they remain in their country of origin or migrate to higher-income countries, such as Australia, Aotearoa New Zealand or the United States of America. We sought to determine whether the CVD health needs of Pacific people vary according to their ethnicity or place of birth. Methods We conducted a systematic review of medical research databases and grey literature to identify relevant data published up to 2020. Texts were included if they contained original data stratified by Pacific-specific ethnicity or place of birth on the burden or management of CVD, and were assessed as having good quality using a National Heart, Lung, and Blood Institute quality assessment tool. The protocol for this review was registered with the Open Science Forum (https://doi.org/10.17605/OSF.IO/X7NR6). Results Of 3679 texts identified, 310 full texts were reviewed and the quality of 23 of these assessed, using the pre-defined search strategy. Six items (four reports, one article, one webpage) of good quality met the review eligibility criteria. All included texts provided data on epidemiology but only one reported on the management of CVD. Four texts were of Pacific populations in Pacific Island countries and two were of Pacific diaspora in other countries. Data from the Global Burden of Disease study, which provided estimates for the greatest number of Pacific countries, showed substantial differences in mortality rates between Pacific countries for every CVD type. For example, the mortality rate per 100,000 for ischemic heart disease (IHD) ranged from 103.41 in the Cook Islands to 430.35 in the Solomon Islands. A New Zealand-based report showed differences in CVD rates by Pacific ethnicity (e.g. the age-standardised prevalence of IHD per 1,000 population in Auckland ranged from 107.8 (Niuean) to 138 among Cook Islands Māori (p < 0.001)). Conclusions This review of published studies reveals that the epidemiology of CVD among Pacific people varies by specific ethnic groups, place of birth, and country of residence. There is a critical need for high-quality contemporary ethnic-specific Pacific data to respond to the diverse CVD health needs in these underrepresented groups. Supplementary Information The online version contains supplementary material available at 10.1186/s12872-021-02313-x.
Collapse
Affiliation(s)
- Julie Winter-Smith
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland Mail Centre, Private Bag 92019, Auckland, 1142, New Zealand.
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland Mail Centre, Private Bag 92019, Auckland, 1142, New Zealand
| | - Matire Harwood
- Department of General Practice and Primary Health Care, Faculty of Medical and Health Sciences, The University of Auckland, Auckland Mail Centre, Private Bag 92019, Auckland, 1142, New Zealand
| | - Shanthi Ameratunga
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland Mail Centre, Private Bag 92019, Auckland, 1142, New Zealand.,Population Health Directorate, Counties Manukau Health, Private Bag 93311, Otahuhu, Auckland, 1640, New Zealand
| | - Corina Grey
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland Mail Centre, Private Bag 92019, Auckland, 1142, New Zealand.,Performance Improvement, Auckland District Health Board, Auckland Mail Centre, Private Bag 92189, Auckland, 1142, New Zealand
| |
Collapse
|
20
|
Chan DZL, Kerr A, Grey C, Selak V, Lee MAW, Lund M, Poppe K, Doughty RN. Contrasting trends in heart failure incidence in younger and older New Zealanders, 2006-2018. Heart 2021; 108:300-306. [PMID: 34686566 DOI: 10.1136/heartjnl-2021-319853] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Accepted: 09/29/2021] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVE Studies indicate that age-standardised heart failure (HF) incidence has been decreasing internationally; however, contrasting trends in different age groups have been reported, with rates increasing in younger people and decreasing in the elderly. We aimed to describe age-specific trends in HF incidence in New Zealand (NZ). METHODS In this nationwide data linkage study, we used routinely collected hospitalisation data to identify incident HF hospitalisations in NZ residents aged ≥20 years between 2006 and 2018. Age-specific and age-standardised incidence rates were calculated for each calendar year. Joinpoint regression was used to compare incidence trends. RESULTS 116 113 incident HF hospitalisations were identified over the 13-year study period. Between 2006 and 2013, age-standardised incidence decreased from 403 to 323 per 100 000 (annual percentage change (APC) -2.6%, 95% CI -3.6 to -1.6%). This reduction then plateaued between 2013 and 2018 (APC 0.8%, 95% CI -0.8 to 2.5%). Between 2006 and 2018, rates in individuals aged 20-49 years old increased by 1.5% per year (95% CI 0.3 to 2.7%) and decreased in those aged ≥80 years old by 1.2% per year (95% CI -1.7 to -0.7%). Rates in individuals aged 50-79 years old initially declined from 2006 to 2013, and then remained stable or increased from 2013 to 2018. The proportion of HF hospitalisations associated with ischaemic heart disease decreased from 35.1% in 2006 to 28.0% in 2018. CONCLUSION HF remains an important problem in NZ. The decline in overall incidence has plateaued since 2013 due to increasing rates of HF in younger age groups despite an ongoing decline in the elderly.
Collapse
Affiliation(s)
- Daniel Z L Chan
- Cardiology, Counties Manukau District Health Board, Auckland, New Zealand .,Greenlane Cardiovascular Service, Auckland District Health Board, Auckland, New Zealand
| | - Andrew Kerr
- Cardiology, Counties Manukau District Health Board, Auckland, New Zealand.,Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Corina Grey
- Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand.,Performance Improvement, Auckland District Health Board, Auckland, New Zealand
| | - Vanessa Selak
- Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Mildred Ai Wei Lee
- Cardiology, Counties Manukau District Health Board, Auckland, New Zealand
| | - Mayanna Lund
- Cardiology, Counties Manukau District Health Board, Auckland, New Zealand
| | - Katrina Poppe
- Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Rob N Doughty
- Greenlane Cardiovascular Service, Auckland District Health Board, Auckland, New Zealand.,Department of Medicine, University of Auckland, Auckland, New Zealand
| |
Collapse
|
21
|
Tane T, Selak V, Hawkins K, Lata V, Murray J, Nicholls D, Peihopa A, Rice N, Harwood M. Māori and Pacific peoples' experiences of a Māori-led diabetes programme. N Z Med J 2021; 134:79-89. [PMID: 34695079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
AIM Type 2 diabetes mellitus (T2DM) disproportionately affects Māori and Pacific peoples in Aotearoa (New Zealand). Despite this, the lived experiences of T2DM and its management by Māori and Pacific peoples are scarcely acknowledged in health literature. The present study examines the lived experiences of T2DM by Māori and Pacific participants in the Mana Tū diabetes programme. Mana Tū is a Māori-led diabetes support programme co-designed by the National Hauora Coalition (NHC) alongside patients with diabetes, clinicians, health service planners and whānau ora providers. METHOD The study used qualitative methods underpinned by Kaupapa Māori (Māori approaches) approaches. Twenty-two semi-structured interviews were conducted with participants of the Mana Tū diabetes programme and their whānau (thirteen Māori, 9 Pacific) from Tāmaki Makaurau (Auckland) and Te Tai Tokerau (Northland). RESULTS The study identified barriers, facilitators and motivators for participants to live well with T2DM. Four key themes were constituted: (1) whānau experience of T2DM, (2) cultural safety in healthcare interactions, (3) whānau ora (collective family wellbeing) and (4) Kaupapa Māori approaches to health interventions. Themes were consistent across Māori and Pacific participants. CONCLUSION Findings suggest that Māori-led health interventions can better support Māori and Pacific people living with T2DM and are needed to ensure these communities receive appropriate, responsive and equitable healthcare.
Collapse
Affiliation(s)
- Taria Tane
- Independent Researcher, Ora Project Solutions: Te Tai Tokerau Northland
| | - Vanessa Selak
- Senior Lecturer, Section of Epidemiology & Biostatistics, University of Auckland: Tāmaki Makaurau
| | - Kimiora Hawkins
- Mana Tū Kai Manaaki, Whangaroa Health Services: Te Tai Tokerau Northland
| | - Vanita Lata
- Mana Tū Kai Manaaki, Tamaki Family Health Centre: Tāmaki Makarau Auckland
| | - Jonathan Murray
- Leader, Primary Health Network, National Hauora Coalition: Tāmaki Makarau Auckland
| | - DeAnn Nicholls
- Mana Tū Kai Manaaki, Papakura Marae Health Clinic: Tāmaki Makarau Auckland
| | - Amelia Peihopa
- Mana Tū Kai Manaaki, The Drs New Lynn: Tāmaki Makarau Auckland
| | - Ngaraiti Rice
- Kaiwhakamana, Here Toitū, National Hauora Coalition: Tāmaki Makarau Auckland
| | - Matire Harwood
- Associate Professor, School of Population Health, University of Auckland: Tāmaki Makaurau
| |
Collapse
|
22
|
Nicholls M, Hamilton S, Jones P, Frampton C, Anderson N, Tauranga M, Beck S, Cadzow A, Cadzow N, Chiang A, Fayerberg E, Hayward L, MacLean A, McLeay A, Moran S, Muthu A, Rogan A, Rolton N, Sagarin M, Tan E, Tomlin F, Yates K, Selak V. Workplace wellbeing in emergency departments in Aotearoa New Zealand 2020. N Z Med J 2021; 134:96-110. [PMID: 34531600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
AIM To quantify staff burnout and wellbeing in emergency departments (EDs) throughout New Zealand (NZ). METHODS A national cross sectional electronic survey of New Zealand clinical and non-clinical ED staff was conducted between 9 March and 3 April 2020. Burnout and wellbeing were assessed using the Copenhagen Burnout Inventory (CBI) and a variety of quantitative measures. Differences between measures were assessed by demography and work role using univariate analyses. Multivariate analyses assessed associations between burnout and wellbeing. RESULTS 1,372 staff responded from 22 EDs around New Zealand (response rate 43%). Most were female (n=678, 63%), NZ European (n=799, 59%), aged 20-39 years (n=743, 54%) and nurses (n=711, 52%). The overall prevalence of personal burnout was 60%, work-related burnout 55% and patient-related burnout 19%. There was a wide variation of burnout across all EDs. Females and nurses showed the highest degree of burnout by gender and role, respectively. Measures of wellbeing with significant negative correlations with burnout were work-related happiness, work-life balance, job satisfaction and perceived workplace excellence. Work stress had significant positive correlation with burnout. CONCLUSION New Zealand ED staff have a high degree of burnout. Safety, financial sustainability and quality of care are likely being adversely affected. Stakeholders can be informed by findings from this study to inspire meaningful interventions in EDs and throughout the New Zealand healthcare system.
Collapse
Affiliation(s)
- Mike Nicholls
- Emergency Department, Auckland City Hospital, Auckland District Health Board
| | - Suzanne Hamilton
- Emergency Department, Christchurch Public Hospital, Canterbury District Health Board. Lead author, local site investigator, data collection, drafted the manuscript, edited the manuscript, gave final approval for the version to be published, and agrees to be accountable for all aspects of the work
| | - Peter Jones
- Emergency Department, Auckland City Hospital, Auckland District Health Board and Dept of Surgery, Faculty of Medical and Health Sciences, University of Auckland
| | | | - Natalie Anderson
- Emergency Department, Auckland City Hospital, Auckland District Health Board and School of Nursing, Faculty of Medical and Health Sciences, University of Auckland
| | - Marama Tauranga
- Taranaki, Ngāti Maniapoto, Tainui; Manukura: Executive Director Toi, Bay of Plenty District Health Board
| | - Sierra Beck
- Emergency Department, Dunedin Hospital SDHB; and Department of Medicine, University of Otago
| | - Alastair Cadzow
- Emergency Department, Timaru Hospital, South Canterbury District Health Board
| | - Natalie Cadzow
- Emergency Department, Timaru Hospital, South Canterbury District Health Board
| | - Arthur Chiang
- Emergency Department, Timaru Hospital, South Canterbury District Health Board; Department of Medicine, University of Otago
| | | | | | - Alastair MacLean
- Emergency Department, Tauranga Hospital, Bay of Plenty District Health Board
| | - Adam McLeay
- Emergency Department, Southland Hospital, Southern District Health Board
| | | | - Alexandra Muthu
- Occupational and Environmental Physician, Auckland District Health Board
| | - Alice Rogan
- Emergency Department, Wellington Regional Hospital, CCDHB; Emergency Department Hutt Hospital, HVDHB; and Department of Surgery and Anaesthesia, University of Otago, Wellington
| | - Nikki Rolton
- Emergency Department, Wairau Hospital, Nelson Marlborough District Health Board
| | - Mark Sagarin
- Emergency Departments Hawera and Taranaki Base Hospitals, Taranaki District Health Board
| | - Eunicia Tan
- Emergency Department, Middlemore Hospital, Counties Manukau Health; and Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland
| | - Fay Tomlin
- Wairarapa Hospital, Wairarapa District Health Board
| | - Kim Yates
- Emergency Departments North Shore & Waitakere Hospitals, Waitematā District Health Board and Centre for Medical and Health Science Education, Faculty of Medical and Health Sciences, University of Auckland
| | - Vanessa Selak
- Senior Lecturer and Public Health Physician, University of Auckland
| |
Collapse
|
23
|
Myint TTW, Selak V, Elwood JM. 601Is in-situ melanoma a precursor of invasive melanoma; a New Zealand study. Int J Epidemiol 2021. [DOI: 10.1093/ije/dyab168.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Melanoma is diagnosed as either in-situ or invasive disease. The relationship between the two diseases is unclear. If every in-situ is an early stage of invasive melanoma, diagnosis and removal of in-situ lesions should reduce the incidence of invasive melanoma. If the association is more complex, the excision of in-situ lesions might not effectively prevent invasive disease and may represent overdiagnosis.
Methods
A population-based cohort study involved all patients diagnosed with either in-situ or invasive melanoma from the New Zealand Cancer Registry between 2001 and 2017. The pattern of in-situ and invasive melanoma was compared by incidence, trends, and key patient characteristics (age at diagnosis, sex, body site, and ethnicity).
Results
The incidence of in-situ melanoma increased annually by 3.77% whereas that of invasive melanoma was relatively stable (annual increase 0.04%) over the study period. The pattern of in-situ and invasive melanoma was similar by sex and ethnicity but differed by body site. Since the distribution of melanoma for age at diagnosis was highly influenced by body site and sex, it was difficult to compare between the two diseases. The observed risk of invasive melanoma among in-situ cohort was four times higher than that expected among general population.
Conclusions
Not every in-situ was a precursor of invasive melanoma, but some did progress to an invasive lesion.
Key-messages
Plans should be considered to compare the potential harms and benefits of the screening and excision of in-situ melanoma.
Collapse
|
24
|
Selak V, Crengle S, Harwood M, Murton S, Crampton P. Emergency COVID-19 funding to general practices in early 2020: lessons for future allocation to support equity. N Z Med J 2021; 134:102-110. [PMID: 34239149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
AIM To (1) describe the distribution of Ministry of Health (MOH) COVID-19 emergency funding to general practices in March and April 2020 and (2) consider whether further funding to general practices should be allocated differently to support equity for patients. METHODS Emergency funding allocation criteria and funding amounts by general practice were obtained from the MOH. Practices were stratified according to their proportion of high-needs enrolled patients (Māori, Pacific or living in an area with the highest quintile of socioeconomic deprivation). Funding per practice was calculated for separate and total payments according to practice stratum of high-needs enrolled patients. RESULTS The median combined March and April funding for general practices with 80% high-needs patients was 28% higher per practice ($36,674 vs $28,686) and 48% higher per patient ($10.50 vs $7.11) compared with the funding received by general practices with fewer than 20% high-needs patients. Although the March allocation did increase funding for high-needs patients, the April allocation did not. CONCLUSIONS Emergency support funding for general practices was organised by the MOH at short notice and in exceptional circumstances. In the future, the MOH should apply pro-equity resource allocation in all emergencies, as with other circumstances.
Collapse
Affiliation(s)
- Vanessa Selak
- Senior Lecturer, Epidemiology & Biostatistics, University of Auckland, Auckland
| | - Sue Crengle
- Associate Professor, Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin
| | - Matire Harwood
- Associate Professor, General Practice and Primary Healthcare, University of Auckland, Auckland
| | - Samantha Murton
- Senior Lecturer, Primary Health Care and General Practice, University of Otago, Wellington
| | - Peter Crampton
- Professor, Kōhatu, Centre for Hauora Māori, University of Otago, Dunedin
| |
Collapse
|
25
|
Anderson N, Pio F, Jones P, Selak V, Tan E, Beck S, Hamilton S, Rogan A, Yates K, Sagarin M, McLeay A, MacLean A, Fayerberg E, Hayward L, Chiang A, Cadzow A, Cadzow N, Moran S, Nicholls M. Facilitators, barriers and opportunities in workplace wellbeing: A national survey of emergency department staff. Int Emerg Nurs 2021; 57:101046. [PMID: 34243105 DOI: 10.1016/j.ienj.2021.101046] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 05/28/2021] [Accepted: 06/14/2021] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Emergency department (ED) staff face daily exposure to the illness, injury, intoxication, violence and distress of others. Rates of clinician burnout are high and associated with poor patient outcomes. This study sought to measure the prevalence of burnout in ED personnel as well as determine the important facilitators of and barriers to workplace wellbeing. METHOD An anonymous online survey including six open-ended questions on workplace wellbeing was completed by 1372 volunteer participants employed as nurses, doctors, allied health or nonclinical roles at 22 EDs in Aotearoa, New Zealand in 2020. Responses to the questions were analysed using a general inductive approach. RESULTS The three key themes that characterise what matters most to participants' workplace wellbeing are: (1) Supportive team culture (2) Delivering excellent patient-centred care and (3) Professional development opportunities. Opportunities to improve wellbeing also focused on enhancements in these three areas. CONCLUSION In order to optimise workplace wellbeing, emergency departments staff value adequate resourcing for high-quality patient care, supportive and cohesive teams and professional development opportunities. Initiatives in these areas may facilitate staff wellbeing as well as improving safety and quality of patient care.
Collapse
Affiliation(s)
- Natalie Anderson
- Faculty of Medical & Health Sciences, University of Auckland, New Zealand; Emergency Department, Auckland City Hospital, Auckland District Health Board, New Zealand.
| | - Fofoa Pio
- Malatest International, Auckland, New Zealand
| | - Peter Jones
- Faculty of Medical & Health Sciences, University of Auckland, New Zealand; Emergency Department, Auckland City Hospital, Auckland District Health Board, New Zealand
| | - Vanessa Selak
- Faculty of Medical & Health Sciences, University of Auckland, New Zealand
| | - Eunicia Tan
- Faculty of Medical & Health Sciences, University of Auckland, New Zealand; Emergency Department, Middlemore Hospital, Counties Manukau Health, New Zealand
| | - Sierra Beck
- Division of Health Sciences, University of Otago, New Zealand; Emergency Department, Dunedin Hospital, Southern District Health Board, New Zealand
| | - Suzanne Hamilton
- Emergency Department, Christchurch Hospital, Canterbury District Health Board, New Zealand; Emergency Department, Wellington Hospital, Capital & Coast District Health Board, New Zealand
| | - Alice Rogan
- Division of Health Sciences, University of Otago, New Zealand; Emergency Department, Christchurch Hospital, Canterbury District Health Board, New Zealand
| | - Kim Yates
- Faculty of Medical & Health Sciences, University of Auckland, New Zealand; Emergency Departments, North Shore & Waitakere Hospitals, Waitematā District Health Board, New Zealand
| | - Mark Sagarin
- Emergency Department, Taranaki Base Hospital, Taranaki District Health Board, New Zealand
| | - Adam McLeay
- Emergency Department, Southland Hospital, Southern District Health Board, New Zealand
| | - Alistair MacLean
- Emergency Department, Tauranga Hospital, Bay of Plenty District Health Board, New Zealand
| | - Eugene Fayerberg
- Emergency Department Whangarei Hospital, Northland District Health Board, New Zealand
| | - Luke Hayward
- Emergency Department, Hutt Hospital. Hutt Valley District Health Board, New Zealand
| | - Arthur Chiang
- Division of Health Sciences, University of Otago, New Zealand; Emergency Department, Timaru Hospital, South Canterbury District Health Board, New Zealand
| | - Alastair Cadzow
- Emergency Department, Timaru Hospital, South Canterbury District Health Board, New Zealand
| | - Natalie Cadzow
- Emergency Department, Timaru Hospital, South Canterbury District Health Board, New Zealand
| | - Suzanne Moran
- Emergency Department, Rotorua Hospital, Lakes District Health Board, New Zealand
| | - Mike Nicholls
- Faculty of Medical & Health Sciences, University of Auckland, New Zealand; Emergency Department, Auckland City Hospital, Auckland District Health Board, New Zealand
| |
Collapse
|
26
|
Pylypchuk R, Wells S, Kerr A, Poppe K, Harwood M, Mehta S, Grey C, Wu BP, Selak V, Drury PL, Chan WC, Orr-Walker B, Murphy R, Mann J, Krebs JD, Zhao J, Jackson R. Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study. Lancet 2021; 397:2264-2274. [PMID: 34089656 DOI: 10.1016/s0140-6736(21)00572-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 02/22/2021] [Accepted: 03/02/2021] [Indexed: 12/23/2022]
Abstract
BACKGROUND Until recently, most patients with diabetes worldwide have been diagnosed when symptomatic and have high cardiovascular risk, meaning most should be prescribed cardiovascular preventive medications. However, in New Zealand, a world-first national programme led to approximately 90% of eligible adults being screened for diabetes by 2016, up from 50% in 2012, identifying many asymptomatic patients with recent-onset diabetes. We hypothesised that cardiovascular risk prediction equations derived before widespread screening would now significantly overestimate risk in screen-detected patients. METHODS New Zealanders aged 30-74 years with type 2 diabetes and without known cardiovascular disease, heart failure, or substantial renal impairment were identified from the 400 000-person PREDICT primary care cohort study between Oct 27, 2004, and Dec 30, 2016, covering the period before and after widespread screening. Sex-specific equations estimating 5-year risk of cardiovascular disease were developed using Cox regression models, with 18 prespecified predictors, including diabetes-related and renal function measures. Equation performance was compared with an equivalent equation derived in the New Zealand Diabetes Cohort Study (NZDCS), which recruited between 2000 and 2006, before widespread screening. FINDINGS 46 652 participants were included in the PREDICT-1° Diabetes subcohort, of whom 4114 experienced first cardiovascular events during follow-up (median 5·2 years, IQR 3·3-7·4). 14 829 (31·8%) were not taking oral hypoglycaemic medications or insulin at baseline. Median 5-year cardiovascular risk estimated by the new equations was 4·0% (IQR 2·3-6·8) in women and 7·1% (4·5-11·2) in men. The older NZDCS equation overestimated median cardiovascular risk by three times in women (median 14·2% [9·7-20·0]) and two times in men (17·1% [4·5-20·0]). Model and discrimination performance measures for PREDICT-1° Diabetse equations were also significantly better than for the NZDCS equation (eg, for women: R2=32% [95% CI 29-34], Harrell's C=0·73 [0·72-0·74], Royston's D=1·410 [1·330-1·490] vs R2=24% [21-26], C=0·69 [0·67-0·70], and D=1·147 [1·107-1·187]). INTERPRETATION International treatment guidelines still consider most people with diabetes to be at high cardiovascular risk; however, we show that recent widespread diabetes screening has radically changed the cardiovascular risk profile of people with diabetes in New Zealand. Many of these patients have normal renal function, are not dispensed glucose-lowering medications, and have low cardiovascular risk. These findings have clear international implications as increased diabetes screening is inevitable due to increasing obesity, simpler screening tests, and the introduction of new-generation glucose-lowering medications that prevent cardiovascular events. Cardiovascular risk prediction equations derived from contemporary diabetes populations, with multiple diabetes-related and renal function predictors, will be required to better differentiate between low-risk and high-risk patients in this increasingly heterogeneous population and to inform appropriate non-pharmacological management and cost-effective targeting of expensive new medications. FUNDING Health Research Council of New Zealand, Heart Foundation of New Zealand, and Healthier Lives National Science Challenge.
Collapse
Affiliation(s)
- Romana Pylypchuk
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Sue Wells
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Andrew Kerr
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Department of Cardiology, Middlemore Hospital, Auckland, New Zealand
| | - Katrina Poppe
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Matire Harwood
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Suneela Mehta
- Planning, Funding and Outcome Teams, Waitemata District Health Board, Auckland, New Zealand
| | - Corina Grey
- Strategy and Performance Improvement Teams, Auckland District Health Board, Auckland, New Zealand
| | - Billy P Wu
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Vanessa Selak
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | | | - Wing Cheuk Chan
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Population Health, Counties Manukau District Health Board, Auckland, New Zealand
| | | | - Rinki Murphy
- School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Jim Mann
- Department of Medicine, University of Otago, Dunedin, New Zealand
| | - Jeremy D Krebs
- Department of Medicine, University of Otago, Wellington, New Zealand
| | - Jinfeng Zhao
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Rod Jackson
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
| |
Collapse
|
27
|
Tse WC, Grey C, Harwood M, Jackson R, Kerr A, Mehta S, Poppe K, Pylypchuk R, Wells S, Selak V. Risk of major bleeding by ethnicity and socioeconomic deprivation among 488,107 people in primary care: a cohort study. BMC Cardiovasc Disord 2021; 21:206. [PMID: 33892644 PMCID: PMC8063422 DOI: 10.1186/s12872-021-01993-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 04/07/2021] [Indexed: 12/03/2022] Open
Abstract
Background Antithrombotic medications (antiplatelets and anticoagulants) reduce the risk of cardiovascular disease (CVD), but with the disadvantage of increasing bleeding risk. Ethnicity and socioeconomic deprivation are independent predictors of major bleeds among patients without CVD, but it is unclear whether they are also predictors of major bleeds among patients with CVD or atrial fibrillation (AF) after adjustment for clinical variables. Methods Prospective cohort study of 488,107 people in New Zealand Primary Care (including 64,420 Māori, the indigenous people of New Zealand) aged 30–79 years who had their CVD risk assessed between 2007 and 2016. Participants were divided into three mutually exclusive subgroups: (1) AF with or without CVD (n = 15,212), (2) CVD and no AF (n = 43,790), (3) no CVD or AF (n = 429,105). Adjusted hazards ratios (adjHRs) were estimated from Cox proportional hazards models predicting major bleeding risk for each of the three subgroups to determine whether ethnicity and socioeconomic deprivation are independent predictors of major bleeds in different cardiovascular risk groups. Results In all three subgroups (AF, CVD, no CVD/AF), Māori (adjHR 1.63 [1.39–1.91], 1.24 [1.09–1.42], 1.57 [95% CI 1.45–1.70], respectively), Pacific people (adjHR 1.90 [1.58–2.28], 1.30 [1.12–1.51], 1.62 [95% CI 1.49–1.75], respectively) and Chinese people (adjHR 1.53 [1.08–2.16], 1.15 [0.90–1.47], 1.13 [95% CI 1.01–1.26], respectively) were at increased risk of a major bleed compared to Europeans, although for Chinese people the effect did not reach statistical significance in the CVD subgroup. Compared to Europeans, Māori and Pacific peoples were generally at increased risk of all bleed types (gastrointestinal, intracranial and other bleeds). An increased risk of intracranial bleeds was observed among Chinese and Other Asian people and, in the CVD and no CVD/AF subgroups, among Indian people. Increasing socioeconomic deprivation was also associated with increased risk of a major bleed in all three subgroups (adjHR 1.07 [1.02–1.12], 1.07 [1.03–1.10], 1.10 [95% CI 1.08–1.12], respectively, for each increase in socioeconomic deprivation quintile). Conclusion Ethnicity and socioeconomic status should be considered in bleeding risk assessments to guide the use of antithrombotic medication for the management of AF and CVD. Supplementary Information The online version contains supplementary material available at 10.1186/s12872-021-01993-9.
Collapse
Affiliation(s)
- Wai Chung Tse
- School of Medicine, Monash University, Clayton, Australia
| | - Corina Grey
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
| | - Matire Harwood
- General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand
| | - Rod Jackson
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
| | - Andrew Kerr
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.,Middlemore Hospital, Auckland, New Zealand
| | - Suneela Mehta
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
| | - Katrina Poppe
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
| | - Romana Pylypchuk
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
| | - Sue Wells
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
| |
Collapse
|
28
|
Wang N, Salam A, Webster R, de Silva A, Guggilla R, Stepien S, Mysore J, Billot L, Jan S, Maulik PK, Naik N, Selak V, Thom S, Prabhakaran D, Patel A, Rodgers A. Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial. JAMA Cardiol 2021; 5:1219-1226. [PMID: 32717045 DOI: 10.1001/jamacardio.2020.2739] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Importance Fixed-dose combination (FDC) therapies are being increasingly recommended for initial or early management of patients with hypertension, as they reduce treatment complexity and potentially reduce therapeutic inertia. Objective To investigate the association of antihypertensive triple drug FDC therapy with therapeutic inertia and prescribing patterns compared with usual care. Design, Setting, and Participants A post hoc analysis of the Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension (TRIUMPH) study, a randomized clinical trial of 700 patients with hypertension, was conducted. Patients were enrolled from 11 urban hospital clinics in Sri Lanka from February 2016 to May 2017; follow-up ended in October 2017. Data were analyzed from September to November 2019. Interventions Once-daily FDC antihypertensive pill (telmisartan, 20 mg; amlodipine, 2.5 mg; and chlorthalidone, 12.5 mg) or usual care. Main Outcomes and Measures Therapeutic inertia, defined as not intensifying therapy in those with blood pressure (BP) above target, was assessed at baseline and during follow-up visits. Prescribing patterns were characterized by BP-lowering drug class and treatment regimen potency. Predictors of therapeutic inertia were assessed with binomial logistic regression. Results Of the 700 included patients, 403 (57.6%) were female, and the mean (SD) age was 56 (11) years. Among patients who did not reach the BP target, therapeutic inertia was more common in the triple pill group compared with the usual care group at the week 6 visit (92 of 106 [86.8%] vs 124 of 194 [63.9%]; P < .001) and week 12 visit (81 of 90 [90%] vs 116 of 179 [64.8%]; P < .001). At the end of the study, 221 of 318 patients in the triple pill group (69.5%) and 182 of 329 patients in the usual care group (55.3%) reached BP targets. Among those who received treatment intensification, the increase in estimated regimen potency was greater in the triple pill group compared with the usual care group at baseline (predicted mean [SD] increase in regimen potency: triple pill, 15 [6] mm Hg; usual care, 10 [5] mm Hg; P < .001), whereas there were no significant differences at the week 6 or at week 12 visit. Clinic systolic BP level was the only consistent predictor of treatment intensification during follow-up. During follow-up, there were 23 vs 54 unique treatment regimens per 100 treated patients in the triple pill vs usual care groups, respectively (P < .001). Conclusions and Relevance Triple pill FDC therapy was associated with greater rates of therapeutic inertia compared with usual care. Despite this, triple pill FDC therapy substantially simplified prescribing patterns and improved 6-month BP control rates compared with usual care. Further improvements in hypertension control could be achieved by addressing therapeutic inertia among the minority of patients who do not achieve BP control after initial FDC therapy. Trial Registration ANZCTR Identifier: ACTRN12612001120864.
Collapse
Affiliation(s)
- Nelson Wang
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | - Abdul Salam
- The George Institute for Global Health, New Delhi, India
| | - Ruth Webster
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | - Asita de Silva
- Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
| | - Rama Guggilla
- Division of Dentistry, Division of Medical Education in English, Department of Population Medicine and Civilization Diseases Prevention, Faculty of Medicine, Medical University of Bialystok, Bialystok, Poland
| | - Sandrine Stepien
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | - Jayanthi Mysore
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | - Laurent Billot
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | - Stephen Jan
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | | | - Nitish Naik
- All India Institute of Medical Sciences, New Delhi, India
| | - Vanessa Selak
- Department of Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| | - Simon Thom
- Department of Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand
| | - Dorairaj Prabhakaran
- Centre for Chronic Disease Control and Public Health Foundation, New Delhi, India
| | - Anushka Patel
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | - Anthony Rodgers
- The George Institute for Global Health, The University of New South Wales, Sydney, Australia
| | | |
Collapse
|
29
|
Mehta S, Zhao J, Poppe K, Kerr AJ, Wells S, Exeter DJ, Selak V, Grey C, Jackson R. Cardiovascular preventive pharmacotherapy stratified by predicted cardiovascular risk: a national data linkage study. Eur J Prev Cardiol 2021; 28:1905-1913. [PMID: 33580793 DOI: 10.1093/eurjpc/zwaa168] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 12/12/2020] [Accepted: 01/09/2021] [Indexed: 11/13/2022]
Abstract
AIMS Cardiovascular disease (CVD) risk management guided by predicted CVD risk is widely recommended internationally. This is the first study to examine CVD preventive pharmacotherapy in a whole-of-country primary prevention population, stratified by CVD risk. METHODS AND RESULTS Anonymized individual-level linkage of New Zealand administrative health and non-health data identified 2 250 201 individuals without atherosclerotic CVD, alive, and aged 30-74 years on 31 March 2013. We identified individuals with ≥1 dispensing by community pharmacies of blood pressure lowering (BPL) and/or lipid-lowering (LL) medications at baseline (1 October 2012-31 March 2013) and in 6-month periods between 1 April 2013 and 31 March 2016. Individuals were stratified using 5-year CVD risk equations specifically developed for application in administrative datasets. One-quarter of individuals had ≥5% 5-year risk (the current New Zealand guideline threshold for discussing preventive medications) and 5% met the ≥15% risk threshold for recommended dual therapy. By study end, dual therapy was dispensed to 2%, 18%, 34%, and 49% of individuals with <5%, 5-9%, 10-14%, and ≥15% 5-year risk, respectively. Among those dispensed baseline dual therapy, 83-89% across risk strata were still treated after 3 years. Dual therapy initiation during follow-up occurred among only 13% of high-risk individuals untreated at baseline. People without diabetes and those aged ≥65 years were more likely to remain untreated. CONCLUSION Cardiovascular disease primary preventive pharmacotherapy was strongly associated with predicted CVD risk and, once commenced, was generally continued. However, only half of high-risk individuals received recommended dual therapy and treatment initiation was modest. Individually linked administrative datasets can identify clinically relevant quality improvement opportunities for entire populations.
Collapse
Affiliation(s)
- Suneela Mehta
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Jinfeng Zhao
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Katrina Poppe
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Andrew J Kerr
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.,Cardiology Services, Middlemore Hospital, Auckland, New Zealand
| | - Sue Wells
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Dan J Exeter
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Corina Grey
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.,Performance Improvement, Strategy, Auckland District Health Board, Auckland, New Zealand
| | - Rod Jackson
- Section of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| |
Collapse
|
30
|
Enright JH, Anderson A, Jansen RM, Murray J, Brewer K, Selak V, Harwood M. Iwi (tribal) data collection at a primary health care organisation in Aotearoa. J Prim Health Care 2021; 13:36-43. [PMID: 33785109 DOI: 10.1071/hc20037] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 01/16/2021] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION Indigenous peoples' rights include the right to self-determine one's identity. For Māori, this includes self-assignment of ethnicity, and traditional identities such as Iwi (tribe). New Zealand's Ministry of Health requires health services to collect ethnicity data using standard protocols. Iwi data are also collected by some health services; however, with no health-specific protocols, little is known about Iwi data collection and quality. The National Hauora Coalition (NHC) Primary Healthcare Organisation (PHO) sought to understand Iwi data collection across its network of primary care providers. AIM To understand Iwi data collection at the NHC PHO; specifically, is it being routinely collected, how is it being collected and what are the results? METHODS In 2017, NHC's general practice clinics were invited to submit their enrolment forms, which capture ethnicity and potentially Iwi information, by e-mail to the audit team. Forms were reviewed to determine whether Iwi information was being collected and if so, what question was being used. Iwi numbers were collated from the annual data extract. RESULTS Thirty-three of a total of 35 clinics (94%) submitted their enrolment forms to the audit team. Nine of the 33 clinics (27%) sought Iwi name/s with a specific question on their enrolment form. Six different 'Iwi' questions were used by the nine clinics. The data extract revealed that the NHC had Iwi data for 13% (2672/20,814) of its Māori enrolments. Ngāpuhi were the largest Iwi group at the NHC. DISCUSSION This is the first study to describe the quantity and quality of Iwi data collection in NZ primary care. Standard procedures for collecting, recording and using Iwi data are being developed by the NHC PHO. These could inform national protocols to optimise the quality of Iwi data.
Collapse
Affiliation(s)
| | - Anneka Anderson
- Te Kupenga Hauora Maori, FMHS, University of Auckland, New Zealand
| | | | - Jonathan Murray
- Primary Health Networks, National Hauora Coalition PHO, Auckland, New Zealand
| | - Karen Brewer
- Psychology (Speech Science), Faculty of Science, University of Auckland, New Zealand
| | - Vanessa Selak
- School of Population Health, FMHS, University of Auckland, New Zealand
| | - Matire Harwood
- Department of General Practice and Primary Care, Grafton, FMHS, University of Auckland, New Zealand; and Corresponding author.
| |
Collapse
|
31
|
Grey C, Jackson R, Wells S, Wu B, Pujades-Rodriguez M, Schmidt M, Selak V, Kerr AJ. Both incidence and prevalence of ischaemic heart disease are declining in parallel: a national data-linkage study in New Zealand (ANZACS-QI 52). Eur J Prev Cardiol 2020; 29:321-327. [PMID: 33623988 DOI: 10.1093/eurjpc/zwaa120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 10/18/2020] [Accepted: 10/30/2020] [Indexed: 01/19/2023]
Abstract
AIMS To examine trends in ischaemic heart disease (IHD) incidence and prevalence in New Zealand from 2005 to 2016, using comprehensive linked national hospitalization and mortality data as proxy measures of all significant events. METHODS AND RESULTS Incident and prevalent cases of IHD in people aged ≥25 years were identified using individual patient-linkage of routinely collected ICD-10-coded hospitalization and mortality data. Incidence rates and prevalence proportions were calculated by sex and age group and then age-standardized to the 2016 New Zealand population. Ischaemic heart disease incidence and prevalence declined in men and women in all age groups. The average annual rate of decline in age-standardized IHD incidence was 3.3% for women and 2.7% for men, and the rate of decline in age-standardized IHD prevalence was 3.2% for women and 2.2% for men. Despite a 17% increase in the New Zealand population aged 25 years and over during the study period, the total number of people living with IHD also decreased, particularly in those aged 65 years and older. CONCLUSION In contrast to observations from other countries, where IHD incidence but not IHD prevalence has been falling, declining IHD incidence in New Zealand in recent decades is now mirrored by declining IHD prevalence.
Collapse
Affiliation(s)
- Corina Grey
- Performance Improvement, Auckland District Health Board, Auckland, New Zealand
| | - Rod Jackson
- Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Sue Wells
- Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Billy Wu
- Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | | | - Morten Schmidt
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.,Department of Cardiology, Regional Hospital West Jutland, Herning, Denmark
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Andrew J Kerr
- Department of Medicine and Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand.,Department of Cardiology, Middlemore Hospital, Auckland, New Zealand
| |
Collapse
|
32
|
Selak V, Poppe K, Grey C, Mehta S, Winter-Smith J, Jackson R, Wells S, Exeter D, Kerr A, Riddell T, Harwood M. Ethnic differences in cardiovascular risk profiles among 475,241 adults in primary care in Aotearoa, New Zealand. N Z Med J 2020; 133:14-27. [PMID: 32994634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
AIM In Aotearoa, New Zealand, cardiovascular disease (CVD) burden is greatest among Indigenous Māori, Pacific and Indian people. The aim of this study was to describe CVD risk profiles by ethnicity. METHODS We conducted a cross-sectional analysis of a cohort of people aged 35-74 years who had a CVD risk assessment in primary care between 2004 and 2016. Primary care data were supplemented with linked data from regional/national databases. Comparisons between ethnic groups were made using age-adjusted summaries of continuous or categorical data. RESULTS 475,241 people (43% women) were included. Fourteen percent were Māori, 13% Pacific, 8% Indian, 10% Other Asian and 55% European. Māori and Pacific people had a much higher prevalence of smoking, obesity, heart failure, atrial fibrillation and prior CVD compared with other ethnic groups. Pacific and Indian peoples, and to a lesser extent Māori and Other Asian people, had markedly elevated diabetes prevalence compared with Europeans. Indian men had the highest prevalence of prior coronary heart disease. CONCLUSIONS Māori and Pacific people experience the most significant inequities in exposure to CVD risk factors compared with other ethnic groups. Indians have a high prevalence of diabetes and coronary heart disease. Strong political commitment and cross-sectoral action to implement effective interventions are urgently needed.
Collapse
Affiliation(s)
- Vanessa Selak
- Public Health Physician and Senior Lecturer, School of Population Health, University of Auckland, Auckland
| | - Katrina Poppe
- Senior Research Fellow, School of Population Health, University of Auckland, Auckland
| | - Corina Grey
- Public Health Physician, School of Population Health, University of Auckland, Auckland
| | - Suneela Mehta
- Public Health Physician and Senior Lecturer, School of Population Health, University of Auckland, Auckland
| | - Julie Winter-Smith
- PhD Candidate, School of Population Health, University of Auckland, Auckland
| | - Rod Jackson
- Public Health Physician and Professor, School of Population Health, University of Auckland, Auckland
| | - Sue Wells
- Public Health Physician and Associate Professor, School of Population Health, University of Auckland, Auckland
| | - Daniel Exeter
- Associate Professor, School of Population Health, University of Auckland, Auckland
| | - Andrew Kerr
- Cardiologist and Associate Professor, School of Population Health, University of Auckland, Auckland
| | | | - Matire Harwood
- Associate Professor and GP, Department of General Practice and Primary Health Care, University of Auckland, Auckland
| |
Collapse
|
33
|
Selak V, Rahiri JL, Jackson R, Harwood M. Acknowledging and acting on racism in the health sector in Aotearoa New Zealand. N Z Med J 2020; 133:7-13. [PMID: 32994633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Affiliation(s)
- Vanessa Selak
- Senior Lecturer, Epidemiology and Biostatistics, University of Auckland, Auckland
| | - Jamie-Lee Rahiri
- Fellow in Medical Education, Department of Surgery, University of Auckland, Auckland
| | - Rod Jackson
- Professor, Epidemiology and Biostatistics, University of Auckland, Auckland
| | - Matire Harwood
- Associate Professor, General Practice and Primary Healthcare, University of Auckland, Auckland
| |
Collapse
|
34
|
Wang TKM, Grey C, Jiang Y, Selak V, Bullen C, Jackson RT, Kerr AJ. Trends in cardiovascular outcomes after acute coronary syndrome in New Zealand 2006-2016. Heart 2020; 107:heartjnl-2020-316891. [PMID: 32826288 DOI: 10.1136/heartjnl-2020-316891] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 07/05/2020] [Accepted: 07/14/2020] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVES Characterisation of trends in acute coronary syndrome (ACS) outcomes are critical to informing clinical practice and quality improvement, but there are few recent population studies for ACS. We reviewed the recent trends in the outcomes of ACS in New Zealand (NZ). METHODS All patients with ACS admitted to NZ public hospitals in 2006-2016 were identified from hospital discharge records, and their first ACS hospitalisations per year extracted for analysis. Thirty-day and 1-year death, myocardial infarction, stroke, heart failure and bleeding rates were calculated for each calendar year. Trends in outcome rates were assessed using generalised linear mixed models. RESULTS Total annual ACS hospitalisations decreased from 685 to 424 per 100 000. Using first patient hospitalisations per year (n=1 55 060), we found significant annual declines in all major outcomes except for non-cardiovascular deaths. All-cause mortality fell from 10.5% to 9.1% at 30 days (adjusted OR 0.985 per year change, p<0.001) and from 21.8% to 18.7% at 1 year (OR=0.994, p=0.016). This was related to significant decreases in cardiovascular death at both time points (OR=0.982 and 0.987, respectively, p<0.001), outweighing a slight increase in non-cardiovascular death at 1 year (OR=1.009, p=0.014). One-year rates of myocardial infarction, heart failure, stroke and bleeding rates all decreased significantly over time. CONCLUSION ACS outcomes including all-cause mortality, cardiovascular death, myocardial infarction, stroke, heart failure and bleeding at 30 days and 1 year improved over the last decade in NZ, reflecting successful implementation and advances in prevention, medical and invasive management in ACS over time.
Collapse
Affiliation(s)
- Tom Kai Ming Wang
- Department of Cardiology, Middlemore Hospital, Auckland, New Zealand
| | - Corina Grey
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand
| | - Yannan Jiang
- National Institute for Health Innovation, University of Auckland, Auckland, New Zealand
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand
| | - Chris Bullen
- National Institute for Health Innovation, University of Auckland, Auckland, New Zealand
| | - Rodney T Jackson
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand
| | - Andrew J Kerr
- Department of Cardiology, Middlemore Hospital, Auckland, New Zealand
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand
| |
Collapse
|
35
|
Peiris-John R, Selak V, Robb G, Kool B, Wells S, Sadler L, Wise MR. The State of Quality Improvement Teaching in Medical Schools: A Systematic Review. J Surg Educ 2020; 77:889-904. [PMID: 32057742 DOI: 10.1016/j.jsurg.2020.01.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Accepted: 01/14/2020] [Indexed: 06/10/2023]
Abstract
INTRODUCTION While teaching patient safety and quality improvement (QI) skills to medical students is endorsed as being important, best practice for achieving learner outcomes in QI is particularly unclear. We systematically reviewed QI curricula for medical students to identify approaches to QI training that are associated with positive learner outcomes. METHODS We searched databases (Medline, EMBASE, and Scopus) and article bibliographies for studies published from 2009 to 2018. Studies evaluating QI teaching for medical students in any setting and reporting learner outcomes were included. Educational content, teaching format, achievement of learning outcomes, and methodological features were abstracted. Outcomes assessed were learners' satisfaction, attitudes, knowledge and skills, changes in behavior and clinical processes, and benefits to patients. RESULTS Twenty of 25 curricula targeted medical students exclusively. Most curricula were well accepted by students (11/13 studies), increased their confidence in QI (9/11) and led to knowledge acquisition (17/20). Overall, positive learner outcomes (Kirkpatrick Levels 1 to 4A) were demonstrated across a range of curricular content and teaching modalities. In particular, 2 curricula demonstrated positive changes in learners' behavior (Kirkpatrick Level 3), both incorporating a clinical audit or QI project based in hospitals, and supplemented by didactic lectures. Seven curricula were associated with improvements in processes of care (Kirkpatrick Level 4A) all of which were set in a clinical setting and supplemented by didactic lectures and/or small group sessions. None of the curricula evaluated patient benefits (Kirkpatrick Level 4B). CONCLUSIONS Whilst there is heterogeneity in educational content and teaching methods, most curricula are well accepted and led to learners' knowledge acquisition. Although there is limited evidence for the impact of QI curricula on learner behavior and benefit to patients, and for interprofessional QI curricula, teaching QI in the clinical setting leads to better learner outcomes with location being potentially a surrogate for clinical experience.
Collapse
Affiliation(s)
- Roshini Peiris-John
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Gillian Robb
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Bridget Kool
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Susan Wells
- Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Lynn Sadler
- Women's Health, Auckland City Hospital, Auckland, New Zealand
| | - Michelle R Wise
- Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| |
Collapse
|
36
|
Wells S, Pylypchuk R, Mehta S, Kerr A, Selak V, Poppe K, Grey C, Jackson R. Performance of CVD risk equations for older patients assessed in general practice: a cohort study. N Z Med J 2020; 133:32-55. [PMID: 32595220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
AIMS To investigate how well the New Zealand PREDICT-CVD risk equations, derived in people aged 30-74 years and US Pooled Cohort Equations (PCEs) derived in people aged 40-79 years, perform for older people. METHODS The PREDICT cohort study automatically recruits participants when clinicians use PREDICT software to conduct a CVD risk assessment. We identified patients aged 70 years and over, without prior CVD, renal disease or heart failure who had been risk assessed between 2004 and 2016. Equation performance was assessed in five-year age bands using calibration graphs and standard discrimination metrics. RESULTS 40,161 patients (median 73 years; IQR 71-77) experienced 5,948 CVD events during 185,150 person-years follow-up. PREDICT-CVD equations were well calibrated in 70-74 year olds but underestimated events for women from 75 years and men from 80 years. Discrimination metrics were also poor for these age groups. Recalibrated PCEs overestimated CVD risk in both sexes and had poor discrimination from age 70 years for men and from age 75 years for women. CONCLUSIONS While PREDICT-CVD equations performed better than PCEs, neither performed well. Multimorbidity and competing risks are likely to contribute to the poor performance and new CVD risk equations need to include these factors.
Collapse
Affiliation(s)
- Sue Wells
- School of Population Health, University of Auckland, Auckland
| | | | - Suneela Mehta
- School of Population Health, University of Auckland, Auckland
| | - Andrew Kerr
- Cardiology Department, Middlemore Hospital, Auckland
| | - Vanessa Selak
- School of Population Health, University of Auckland, Auckland
| | - Katrina Poppe
- Department of Medicine, University of Auckland, Auckland
| | - Corina Grey
- School of Population Health, University of Auckland, Auckland
| | - Rod Jackson
- School of Population Health, University of Auckland, Auckland
| |
Collapse
|
37
|
Selak T, Selak V. Communicating risks of obesity before anaesthesia from the patient's perspective: informed consent or fat-shaming? Anaesthesia 2020; 76:170-173. [PMID: 32478866 DOI: 10.1111/anae.15126] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/13/2020] [Indexed: 01/01/2023]
Affiliation(s)
- T Selak
- Department of Anaesthesia, Wollongong Hospital, Wollongong, NSW, Australia
| | - V Selak
- Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| |
Collapse
|
38
|
Wallis KA, Wells S, Selak V, Poppe K. Long-term follow up of older people on diabetes medications: observational study using linked health databases. Aust J Prim Health 2020; 26:306-312. [DOI: 10.1071/py19246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 05/13/2020] [Indexed: 11/23/2022]
Abstract
There is uncertainty about the long-term benefits and risks of diabetes medications in older people. We investigated differences in hypoglycaemia, cardiovascular disease (CVD) or mortality in older people according to diabetes medication, using linked national hospitalisation and mortality data from New Zealand. Adults aged ≥65 years dispensed diabetes medication in 2010 with a baseline glycated haemoglobulin (HbA1c) level (n=18099, mean age 73 years, 50% female) were included and stratified into four groups: metformin-only (42%); metformin-plus-other-oral-hypoglycaemic/s (27%); other-oral/s-only (11%); and any-insulin (20%). Time to first event was analysed with Cox models adjusted for sociodemographic factors; clinical history (prior hospitalisation for diabetes or CVD, and comorbidities); glycated haemoglobin; and CVD medications. Over 7-year follow up, 16% of participants experienced hypoglycaemia, 36% a CVD event and 31% died. Compared with metformin-only, insulin and other oral hypoglycaemic/s were associated with five- to 10-fold long-term increased risk of hypoglycaemia, and increased risk of CVD and death although adjusted survival curves showed no important separation between medication groups for CVD and death with the possible exception of insulin. Although confounding by indication is unable to be eliminated, this study raises further questions about the use of second-line diabetes medications in older people.
Collapse
|
39
|
Wang N, Salam A, Webster R, De Silva A, Guggilla R, Stepien S, Mysore J, Billot L, Jan S, Maulik P, Naik N, Selak V, Thom S, Prabhakaran D, Patel A, Rodgers A. 021 Effects of Low-dose Triple Combination Therapy on Therapeutic Inertia and Prescribing Patterns in Hypertension – Results from the TRIUMPH Trial. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Selak V, Jackson R, Poppe K, Wu B, Harwood M, Grey C, Pylypchuk R, Mehta S, Choi YH, Kerr A, Wells S. Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. Ann Intern Med 2019; 171:529-539. [PMID: 31525775 DOI: 10.7326/m19-1132] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear. OBJECTIVE To identify persons without CVD for whom aspirin would probably result in a net benefit. DESIGN Individualized benefit-harm analysis based on sex-specific risk scores and estimates of the proportional effect of aspirin on CVD and major bleeding from a 2019 meta-analysis. SETTING New Zealand primary care. PARTICIPANTS 245 028 persons (43.6% women) aged 30 to 79 years without established CVD who had their CVD risk assessed between 2012 and 2016. MEASUREMENTS The net effect of aspirin was calculated for each participant by subtracting the number of CVD events likely to be prevented (CVD risk score × proportional effect of aspirin on CVD risk) from the number of major bleeds likely to be caused (major bleed risk score × proportional effect of aspirin on major bleeding risk) over 5 years. RESULTS 2.5% of women and 12.1% of men were likely to have a net benefit from aspirin treatment for 5 years if 1 CVD event was assumed to be equivalent in severity to 1 major bleed, increasing to 21.4% of women and 40.7% of men if 1 CVD event was assumed to be equivalent to 2 major bleeds. Net benefit subgroups had higher baseline CVD risk, higher levels of most established CVD risk factors, and lower levels of bleeding-specific risk factors than net harm subgroups. LIMITATIONS Risk scores and effect estimates were uncertain. Effects of aspirin on cancer outcomes were not considered. Applicability to non-New Zealand populations was not assessed. CONCLUSION For some persons without CVD, aspirin is likely to result in net benefit. PRIMARY FUNDING SOURCE Health Research Council of New Zealand.
Collapse
Affiliation(s)
- Vanessa Selak
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Rod Jackson
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Katrina Poppe
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Billy Wu
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Matire Harwood
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Corina Grey
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Romana Pylypchuk
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Suneela Mehta
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Yeun-Hyang Choi
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| | - Andrew Kerr
- University of Auckland and Middlemore Hospital, Auckland, New Zealand (A.K.)
| | - Sue Wells
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., Y.C., S.W.)
| |
Collapse
|
41
|
Selak V, Bullen C, Arroll B, Doughty R, Doughty R, Grey C, Harwood M, Crengle S. The strong case for government funding of a polypill for the secondary prevention of cardiovascular disease in New Zealand. N Z Med J 2019; 132:77-83. [PMID: 31563929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Wald and Law, who popularised the term 'polypill' in 2003, proposed giving everyone above a certain age a polypill to reduce the burden of cardiovascular disease (CVD). A more compelling potential application, proposed in 2001 by the World Health Organization, is to use a polypill containing antiplatelet, statin and blood pressure-lowering therapy among people with established CVD, in whom the components are already indicated but in whom guideline implementation and adherence are suboptimal. This article outlines relevant international and New Zealand evidence on the likely benefits and harms of a polypill for the secondary prevention of CVD. The evidence indicates that the benefits are likely to outweigh the harms, particularly given the persistence of substantial treatment gaps and inequities in the management of and outcomes in CVD. The time is long overdue for the polypill to be funded for the secondary prevention of CVD.
Collapse
Affiliation(s)
- Vanessa Selak
- Senior Lecturer, Epidemiology & Biostatistics, University of Auckland, Auckland
| | - Chris Bullen
- Professor, National Institute for Health Innovation, University of Auckland, Auckland
| | - Bruce Arroll
- Professor, General Practice and Primary Healthcare, University of Auckland, Auckland
| | - Rob Doughty
- Professor and Chair of Heart Health, School of Medicine, University of Auckland, Auckland
| | - Rob Doughty
- Professor and Chair of Heart Health, School of Medicine, University of Auckland, Auckland
| | - Corina Grey
- Research Fellow, Epidemiology & Biostatistics, University of Auckland, Auckland
| | - Matire Harwood
- Associate Professor, General Practice and Primary Healthcare, University of Auckland, Auckland
| | - Sue Crengle
- Associate Professor, Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin
| |
Collapse
|
42
|
Lung T, Jan S, de Silva HA, Guggilla R, Maulik PK, Naik N, Patel A, de Silva AP, Rajapakse S, Ranasinghe G, Prabhakaran D, Rodgers A, Salam A, Selak V, Stepien S, Thom S, Webster R, Lea-Laba T. Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. Lancet Glob Health 2019; 7:e1359-e1366. [PMID: 31477545 DOI: 10.1016/s2214-109x(19)30343-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 07/10/2019] [Accepted: 07/19/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND Elevated blood pressure incurs a major health and economic burden, particularly in low-income and middle-income countries. The Triple Pill versus Usual Care Management for Patients with Mild-to-Moderate Hypertension (TRIUMPH) trial showed a greater reduction in blood pressure in patients using fixed-combination, low-dose, triple-pill antihypertensive therapy (consisting of amlodipine, telmisartan, and chlorthalidone) than in those receiving usual care in Sri Lanka. We aimed to assess the cost-effectiveness of the triple-pill strategy. METHODS We did a within-trial (6-month) and modelled (10-year) economic evaluation of the TRIUMPH trial, using the health system perspective. Health-care costs, reported in 2017 US dollars, were determined from trial records and published literature. A discrete-time simulation model was developed, extrapolating trial findings of reduced systolic blood pressure to 10-year health-care costs, cardiovascular disease events, and mortality. The primary outcomes were the proportion of people reaching blood pressure targets (at 6 months from baseline) and disability-adjusted life-years (DALYs) averted (at 10 years from baseline). Incremental cost-effectiveness ratios were calculated to estimate the cost per additional participant achieving target blood pressure at 6 months and cost per DALY averted over 10 years. FINDINGS The triple-pill strategy, compared with usual care, cost an additional US$9·63 (95% CI 5·29 to 13·97) per person in the within-trial analysis and $347·75 (285·55 to 412·54) per person in the modelled analysis. Incremental cost-effectiveness ratios were estimated at $7·93 (95% CI 6·59 to 11·84) per participant reaching blood pressure targets at 6 months and $2842·79 (-28·67 to 5714·24) per DALY averted over a 10-year period. INTERPRETATION Compared with usual care, the triple-pill strategy is cost-effective for patients with mild-to-moderate hypertension. Scaled up investment in the triple pill for hypertension management in Sri Lanka should be supported to address the high population burden of cardiovascular disease. FUNDING Australian National Health and Medical Research Council.
Collapse
Affiliation(s)
- Thomas Lung
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
| | - Stephen Jan
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - H Asita de Silva
- Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
| | - Rama Guggilla
- Department of Population Medicine and Civilization Diseases Prevention, Faculty of Medicine with the Division of Dentistry and Division of Medical Education in English, Medical University of Bialystok, Bialystok, Poland
| | - Pallab K Maulik
- The George Institute for Global Health, University of New South Wales, New Delhi, India; The George Institute for Global Health, University of Oxford, Oxford, UK
| | - Nitish Naik
- All India Institute of Medical Sciences, New Delhi, India
| | - Anushka Patel
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| | - Arjuna P de Silva
- Department of Medicines, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
| | - Senaka Rajapakse
- Department of Medicines, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
| | | | | | - Anthony Rodgers
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| | - Abdul Salam
- The George Institute for Global Health, University of New South Wales, Hyderabad, India
| | - Vanessa Selak
- Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Sandrine Stepien
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| | - Simon Thom
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK
| | - Ruth Webster
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| | - Tracey Lea-Laba
- The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
| |
Collapse
|
43
|
Chan D, Ghazali S, Selak V, Lee M, Scott T, Kerr A. What is the Optimal Rate of Invasive Coronary Angiography After Acute Coronary Syndrome? (ANZACS-QI 22). Heart Lung Circ 2019; 29:262-271. [PMID: 30922552 DOI: 10.1016/j.hlc.2019.01.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 12/04/2018] [Accepted: 01/02/2019] [Indexed: 12/22/2022]
Abstract
BACKGROUND Invasive coronary angiography plays a pivotal role in the management of acute coronary syndromes (ACS). Wide variability in its use has been previously documented. Our aim was to investigate whether coronary angiography is being used appropriately prior to discharge after ACS, taking into account relative contraindications of the procedure. METHODS Patients presenting with ACS in 2015 to two large, demographically distinct New Zealand (NZ) District Health Boards (DHBs)-Counties Manukau (CMDHB) and Waitemata (WDHB)-were identified from the NZ Ministry of Health National Dataset using ICD-10-AM codes. Patients' clinical data were obtained from the electronic and paper clinical records. Pre-defined relative contraindications to coronary angiography were identified. RESULTS Of the 3,809 patient admissions coded with ACS, 600 patient admissions (300 from each DHB) were reviewed. Sixty-one (61) (10%) did not meet diagnostic criteria for ACS on review of clinical data and were excluded. Of the patients reviewed, 55% received coronary angiography, with a higher rate in WDHB than CMDHB (61% and 49%, respectively) and 37.5% had relative contraindications documented. The overall rate of angiography was appropriately high in those without a relative contraindication (90.3%) and low in those with one (7.4%). There were fewer patients with relative contraindications in WDHB than CMDHB (36.7% and 48.5%) but the rate of angiography in those with (6.9% and 7.8%) and without (92.5% and 87.5%) contraindications in the two DHBs was similar. CONCLUSIONS The decision to offer coronary angiography after ACS appears to be appropriately influenced by the presence or absence of relative contraindications. Approximately 60% of patients had no documented relative contraindication suggesting that this may be an appropriate angiography rate in New Zealand practice. However, differences between the two DHBs of around 10% appear to be clinically appropriate due to variation in contraindication rates.
Collapse
Affiliation(s)
- Daniel Chan
- Department of Cardiology, Counties Manukau District Health Board, Auckland, New Zealand.
| | - Samia Ghazali
- Department of Cardiology, Counties Manukau District Health Board, Auckland, New Zealand
| | - Vanessa Selak
- Institute for Innovation and Improvement (i(3)), Waitemata District Health Board, Auckland, New Zealand
| | - Mildred Lee
- Department of Cardiology, Counties Manukau District Health Board, Auckland, New Zealand
| | - Tony Scott
- Department of Cardiology, Waitemata District Health Board, Auckland, New Zealand
| | - Andrew Kerr
- Department of Cardiology, Counties Manukau District Health Board, Auckland, New Zealand
| |
Collapse
|
44
|
Selak V, Jackson R, Poppe K, Wu B, Harwood M, Grey C, Pylypchuk R, Mehta S, Kerr A, Wells S. Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. Ann Intern Med 2019; 170:357-368. [PMID: 30802900 DOI: 10.7326/m18-2808] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms. OBJECTIVE To develop prognostic bleeding risk models among persons in whom aspirin might be considered for the primary prevention of cardiovascular disease (CVD). DESIGN Prospective cohort study. SETTING New Zealand primary care. PARTICIPANTS The study cohort comprised 385 191 persons aged 30 to 79 years whose CVD risk was assessed between 2007 and 2016. Those with indications for or contraindications to aspirin and those who were already receiving antiplatelet or anticoagulant therapy were excluded. MEASUREMENTS For each sex, Cox proportional hazards models were developed to predict major bleeding risk; participants were censored at the earliest of the date on which they first met an exclusion criterion, date of death, or study end date (30 June 2017). The main models included the following predictors: demographic characteristics (age, ethnicity, and socioeconomic deprivation), clinical measurements (systolic blood pressure and ratio of total-high-density lipoprotein cholesterol), family history of premature CVD, medical history (smoking, diabetes, bleeding, peptic ulcer disease, cancer, chronic liver disease, chronic pancreatitis, or alcohol-related conditions), and medication use (nonsteroidal anti-inflammatory agents, corticosteroids, and selective serotonin reuptake inhibitors). RESULTS During 1 619 846 person-years of follow-up, 4442 persons had major bleeding events (of which 313 [7%] were fatal). The main models predicted a median 5-year bleeding risk of 1.0% (interquartile range, 0.8% to 1.5%) in women and 1.1% (interquartile range, 0.7% to 1.6%) in men. Plots of predicted-against-observed event rates showed good calibration throughout the risk range. LIMITATION Hemoglobin level, platelet count, and body mass index were excluded from the main models because of high numbers of missing values, and the models were not externally validated in non-New Zealand populations. CONCLUSION Prognostic bleeding risk models were developed that can be used to estimate the absolute bleeding harms of aspirin among persons in whom aspirin is being considered for the primary prevention of CVD. PRIMARY FUNDING SOURCE The Health Research Council of New Zealand.
Collapse
Affiliation(s)
- Vanessa Selak
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Rod Jackson
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Katrina Poppe
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Billy Wu
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Matire Harwood
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Corina Grey
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Romana Pylypchuk
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Suneela Mehta
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| | - Andrew Kerr
- University of Auckland and Middlemore Hospital, Auckland, New Zealand (A.K.)
| | - Sue Wells
- University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., C.G., R.P., S.M., S.W.)
| |
Collapse
|
45
|
Church E, Poppe K, Harwood M, Mehta S, Grey C, Selak V, Marshall MR, Wells S. Relationship between estimated glomerular filtration rate and incident cardiovascular disease in an ethnically diverse primary care cohort. N Z Med J 2019; 132:11-26. [PMID: 30845125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
AIM To investigate eGFR as an independent risk factor for CVD in a New Zealand primary care cohort, stratified by disease status (prior CVD, diabetes or no CVD or diabetes). METHOD The PREDICT-CVD open cohort study is a large, ethnically diverse, New Zealand primary care cohort, generated by using a web-based CVD risk assessment tool. Using encrypted identifiers, participant profiles were linked anonymously to a regional laboratory database (to determine renal function) and to national hospitalisation and mortality datasets. Analyses using a single baseline eGFR measurement were undertaken in three clinical sub-cohorts of participants: those with prior CVD (n=29,742), with diabetes (n=44,416) and with neither CVD nor diabetes (n=192,696). The association between baseline eGFR (by category ≥90, 60-89.9, 30-59.9, and <30ml/min/1.73m2) and incident CVD was analysed with Kaplan Meier plots and Cox regression models. RESULTS After adjustment for traditional CVD risk factors, there was an inverse relationship between CVD risk and eGFR, up to an eGFR of 60ml/min/1.73m2 in all three clinical sub-cohorts, and up to an eGFR of 90ml/min/1.73m2 in the sub-cohort with CVD or diabetes. Compared to eGFR ≥90ml/min/1.73m2, the adjusted hazard ratios of a new CVD event for eGFR <30ml/min/1.73m2 in the CVD, diabetes and no CVD/no diabetes sub-cohorts were 2.29 (95% CI 2.00-2.61), 4.71 (3.92-5.67) and 2.78 (2.05-3.77), respectively. Compared to European/Other ethnic groups, Māori participants remained at greater adjusted risk of a new CVD event in all clinical sub-cohorts and Pacific people only in the no CVD/no diabetes sub-cohort, whereas Indian participants had a similar adjusted risk to European/Other, and Other Asian patients were consistently at lower adjusted risk. Sensitivity analyses for individuals with consecutive eGFR results (>90 days apart) yielded similar results. CONCLUSION This study has confirmed that, in a large ethnically diverse primary care cohort, eGFR is a significant independent predictor of CVD risk, and the risk varies by ethnic group.
Collapse
Affiliation(s)
- Emma Church
- Public Health Medicine Registrar, National Screening Unit, Ministry of Health, New Zealand
| | - Katrina Poppe
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland
| | - Matire Harwood
- School of Population Health, University of Auckland, Auckland, New Zealand
| | - Suneela Mehta
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland
| | - Corina Grey
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland
| | - Vanessa Selak
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland
| | - Mark R Marshall
- Department of Renal Medicine, Middlemore Hospital, Counties Manukau Health, Auckland
| | - Sue Wells
- Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland
| |
Collapse
|
46
|
Selak V, Stewart T, Jiang Y, Reid J, Tane T, Carswell P, Harwood M. Indigenous health worker support for patients with poorly controlled type 2 diabetes: study protocol for a cluster randomised controlled trial of the Mana Tū programme. BMJ Open 2018; 8:e019572. [PMID: 30552239 PMCID: PMC6303687 DOI: 10.1136/bmjopen-2017-019572] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
INTRODUCTION Type 2 diabetes mellitus (T2DM) and its complications are more common among Māori and Pacific people compared with other ethnic groups in New Zealand. Comprehensive and sustained approaches that address social determinants of health are required to address this condition, including culturally specific interventions. Currently, New Zealand has no comprehensive T2DM management programme for Māori or Pacific people. METHODS AND ANALYSIS The Mana Tū programme was developed by a Māori-led collaborative of primary healthcare workers and researchers, and codesigned with whānau (patients and their families) in order to address this gap. The programme is based in primary care and has three major components: a Network hub, Kai Manaaki (skilled case managers who work with whānau with poorly controlled diabetes) and a cross-sector network of services to whom whānau can be referred to address the wider determinants of health. The Network hub supports the delivery of the intervention through training of Kai Manaaki, referrals management, cross-sector network development and quality improvement of the programme. A two-arm cluster randomised controlled trial will be conducted to evaluate the effectiveness of the Mana Tū programme among Māori, Pacific people or those living in areas of high socioeconomic deprivation who also have poorly controlled diabetes (glycated haemoglobin, HbA1c, >65 mmol/mol (8%)), compared with being on a wait list for the programme. A total of 400 participants will be included from 10 general practices (5 practices per group, 40 participants per practice). The primary outcome is HbA1c at 12 months. Secondary outcomes include blood pressure, lipid levels, body mass index and smoking status at 12 months. This protocol outlines the proposed study design and analysis methods. ETHICS AND DISSEMINATION Ethical approval for the trial has been obtained from the New Zealand Health and Disability Ethics Committee (17/NTB/249). Findings will be presented to practices and their patients at appropriate fora, and disseminated widely through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER ACTRN12617001276347; Pre-result.
Collapse
Affiliation(s)
- Vanessa Selak
- Epidemiology & Biostatistics, University of Auckland, Auckland, New Zealand
| | - Tereki Stewart
- Mana Tu, National Hauora Coalition, Auckland, New Zealand
| | - Yannan Jiang
- Department of Statistics, The University of Auckland, Auckland, New Zealand
| | - Jennifer Reid
- Te Kupenga Hauora Māori, University of Auckland, Auckland, New Zealand
| | - Taria Tane
- Mana Tu, National Hauora Coalition, Auckland, New Zealand
| | - Peter Carswell
- Department of Health Systems, University of Auckland, Auckland, New Zealand
| | - Matire Harwood
- Te Kupenga Hauora Māori, University of Auckland, Auckland, New Zealand
| |
Collapse
|
47
|
Harwood M, Tane T, Broome L, Carswell P, Selak V, Reid J, Light P, Stewart T. Mana Tū: a whānau ora approach to type 2 diabetes. N Z Med J 2018; 131:76-83. [PMID: 30408821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
In 2017, the National Hauora Coalition, a Māori-led Primary Health Organisation (PHO), was awarded a Long-Term Conditions Partnership Research grant to test the effectiveness of Mana Tū: a whānau ora approach to type 2 diabetes. With moves to replicate aspects of it in programmes around New Zealand, it is timely to describe the rationale for Mana Tū and the key components of its unique model of care. Mana Tū was developed in response to current ethnic and social inequities in type 2 diabetes rates, outcomes and wider determinants. It attempts to address various system, service and patient factors that impact on the whānau's ability to 'mana tū' or 'stand with authority' when living with a long-term condition. Results, including clinical, implementation and cost-effectiveness data, will be collected and analysed over the next two years.
Collapse
Affiliation(s)
- Matire Harwood
- Te Kupenga Hauora Māori, Faculty of Medical and Health Sciences, Auckland
| | - Taria Tane
- Mana Tū, National Hauora Coalition, Auckland
| | - Laura Broome
- Outcome Services, National Hauora Coalition, Auckland
| | - Peter Carswell
- School of Population Health, University of Auckland, Auckland
| | - Vanessa Selak
- School of Population Health, University of Auckland, Auckland
| | | | - Phil Light
- Outcome Services, National Hauora Coalition, Auckland
| | - Tereki Stewart
- Executive Leadership, National Hauora Coalition, Auckland
| |
Collapse
|
48
|
Ng J, Andrew P, Muir P, Greene M, Mohan S, Knight J, Hider P, Davis P, Seddon M, Scahill S, Harrison J, Zhou L, Selak V, Lawes C, Galgali G, Broad J, Crawley M, Pevreal W, Houston N, Brott T, Ryan D, Peach J, Brant A, Bramley D. Feasibility and reliability of clinical coding surveillance for the routine monitoring of adverse drug events in New Zealand hospitals. N Z Med J 2018; 131:46-60. [PMID: 30359356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
AIM To explore the feasibility and reliability of Clinical Coding Surveillance (CCS) for the routine monitoring of Adverse Drug Events (ADE) and describe the characteristics of harm identified through this approach in a large district health board (DHB). METHOD All hospital admissions at Waitemata DHB from 2015 to 2016 with an ADE-related ICD10-AM code of Y40-Y59, X40-X49 or T36-T50 were extracted from clinical coded data. The data was analysed using descriptive statistics, statistical process control and Pareto charts. Two clinicians assessed a random sample of 140 ADEs for their accuracy against what was clinically documented in medical records. RESULTS A total of 11,999 ADEs were identified in 244,992 admissions (4.9 ADEs per 100 admissions). ADEs were more prevalent in older adults and associated with longer average length of stays and medicines such as analgesics, antibiotics, anticoagulants and diuretics. Only 2,164 (18%) of ADEs were classified as originating within hospital. Of ADEs originating outside of the hospital, the main causes were poisoning by psychotropics, anti-epileptics and anti-parkinsonism agents and non-opioid analgesics. Clinicians agreed that 91% of ADE positive admissions were accurately classified as per clinical documentation. CONCLUSION CCS is a feasible and reliable approach for the routine monitoring of ADEs in hospitals.
Collapse
Affiliation(s)
- Jerome Ng
- Lead Advisor, Improvement, Research & Informatics, Institute for Innovation and Improvement (i3), Waitemata DHB, Auckland
| | - Penny Andrew
- Director, Institute for Innovation and Improvement (i3), Waitemata DHB, Auckland
| | - Paul Muir
- Medical Fellow, Planning, Funding and Outcomes, Waitemata DHB, Auckland
| | - Monique Greene
- Information Analyst, Institute for Innovation and Improvement (i3), Waitemata DHB, Auckland
| | - Sabitha Mohan
- Clinical Coding Auditor, Health Information Group, Waitemata DHB, Auckland
| | - Jacqui Knight
- Clinical Coding Team Leader, Health Information Group, Waitemata DHB, Auckland
| | - Phil Hider
- Senior Lecturer, Department of Population Health, University of Otago, Christchurch
| | - Peter Davis
- Professor, Centre of Methods and Policy Application in the Social Sciences (COMPASS), University of Auckland, Auckland
| | - Mary Seddon
- Independent Consultant, Seddon Healthcare Quality, Auckland
| | - Shane Scahill
- Senior Lecturer, School of Management, Massey University, Auckland
| | - Jeff Harrison
- Associate Professor, School of Pharmacy, University of Auckland, Auckland
| | - Lifeng Zhou
- Chief Advisor for Asian International Collaboration, Waitemata District Health Board, Auckland
| | - Vanessa Selak
- Senior Lecturer, School of Population Health, University of Auckland, Auckland
| | - Carlene Lawes
- Public Health Physician (Surgical), Institute for Innovation and Improvement (i3), Waitemata DHB, Auckland
| | - Geetha Galgali
- Public Health Physician (Maternity), Child, Women and Family, Waitemata DHB, Auckland
| | - Joanna Broad
- Senior Research Fellow, Department of Geriatric Medicine, University of Auckland, Auckland
| | - Marilyn Crawley
- Chief Pharmacist, Pharmacy Department, Waitemata DHB, Auckland
| | - Wynn Pevreal
- Medication Safety Pharmacist, Pharmacy Department, Waitemata DHB, Auckland (Died 24 April 2018)
| | - Neil Houston
- Clinical Director for Safety and Quality in Primary Care, Waitemata DHB, Auckland
| | - Tamzin Brott
- Executive Director-Allied Health, Scientific & Technical Professions, Waitemata DHB, Auckland
| | - David Ryan
- Information Systems Change Manager, Health Information Group, Waitemata DHB, Auckland
| | - Jocelyn Peach
- Director of Nursing and Midwifery, Waitemata DHB, Auckland
| | | | - Dale Bramley
- Chief Executive Officer, Waitemata DHB, Auckland
| |
Collapse
|
49
|
Selak V, Jackson R, Poppe K, Kerr A, Wells S. Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? N Z Med J 2018; 131:19-25. [PMID: 30359352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
AIM The 2018 New Zealand Consensus Statement on cardiovascular disease (CVD) risk assessment and management recommends the use of aspirin in people aged less than 70 years with a five-year CVD risk >15% but without prior CVD. We determined whether the estimated number of CVD events avoided by taking aspirin is likely to exceed the number of additional major bleeds caused by aspirin in this patient population. METHOD Major bleeding rates were obtained from the PREDICT primary care study, a large New Zealand cohort of people eligible for CVD risk assessment, after excluding those with no other indications for (eg, established CVD) or contraindications/cautions (eg, prior major bleed) to aspirin use. We modelled the benefits (CVD events avoided) and harms (additional major bleeds) of aspirin for primary prevention of CVD over five years using hypothetical populations aged 40 to 79 years, stratified by sex, age-group and estimated five-year CVD risk. Two clinical scenarios were modelled, according to whether or not optimisation of lipid- and blood pressure-lowering therapy was required prior to aspirin initiation. RESULTS In both clinical scenarios the number of CVD events prevented by aspirin over five years was estimated to be, on average, more than the number of bleeds caused by aspirin among people aged less than 70 years with estimated five-year CVD risk of >15%. However, the magnitude of the net benefit of aspirin was modest among people aged 60-69 years, particularly if lipid- and blood pressure-lowering therapy had not already been optimised. CONCLUSION The benefits of aspirin are likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of CVD. A more cautious approach to the use of aspirin is appropriate for people aged 60-69 years who are likely to have a smaller net benefit from aspirin, particularly those in whom lipid- and blood pressure-lowering therapy has not already been optimised or who have other bleeding risk factors, such as diabetes or smoking. More specific recommendations will be possible when bleeding risk equations are developed to complement the recently developed New Zealand CVD risk equations.
Collapse
Affiliation(s)
- Vanessa Selak
- Senior Lecturer, Epidemiology & Biostatistics, University of Auckland, Auckland
| | - Rod Jackson
- Professor, Epidemiology & Biostatistics, University of Auckland, Auckland
| | - Katrina Poppe
- Senior Research Fellow, Epidemiology & Biostatistics, University of Auckland, Auckland
| | - Andrew Kerr
- Associate Professor, Epidemiology & Biostatistics, University of Auckland, Auckland; Cardiologist, Middlemore Hospital, Auckland
| | - Sue Wells
- Associate Professor, Epidemiology & Biostatistics, University of Auckland, Auckland
| |
Collapse
|
50
|
Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, Amarasekara S, Amarasena N, Billot L, de Silva AP, Fernando M, Guggilla R, Jan S, Jayawardena J, Maulik PK, Mendis S, Mendis S, Munasinghe J, Naik N, Prabhakaran D, Ranasinghe G, Thom S, Tisserra N, Senaratne V, Wijekoon S, Wijeyasingam S, Rodgers A, Patel A. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA 2018; 320:566-579. [PMID: 30120478 PMCID: PMC6583010 DOI: 10.1001/jama.2018.10359] [Citation(s) in RCA: 100] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
IMPORTANCE Poorly controlled hypertension is a leading global public health problem requiring new treatment strategies. OBJECTIVE To assess whether a low-dose triple combination antihypertensive medication would achieve better blood pressure (BP) control vs usual care. DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label trial of a low-dose triple BP therapy vs usual care for adults with hypertension (systolic BP >140 mm Hg and/or diastolic BP >90 mm Hg; or in patients with diabetes or chronic kidney disease: >130 mm Hg and/or >80 mm Hg) requiring initiation (untreated patients) or escalation (patients receiving monotherapy) of antihypertensive therapy. Patients were enrolled from 11 urban hospital clinics in Sri Lanka from February 2016 to May 2017; follow-up ended in October 2017. INTERVENTIONS A once-daily fixed-dose triple combination pill (20 mg of telmisartan, 2.5 mg of amlodipine, and 12.5 mg of chlorthalidone) therapy (n = 349) or usual care (n = 351). MAIN OUTCOMES AND MEASURES The primary outcome was the proportion achieving target systolic/diastolic BP (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes or chronic kidney disease) at 6 months. Secondary outcomes included mean systolic/diastolic BP difference during follow-up and withdrawal of BP medications due to an adverse event. RESULTS Among 700 randomized patients (mean age, 56 years; 58% women; 29% had diabetes; mean baseline systolic/diastolic BP, 154/90 mm Hg), 675 (96%) completed the trial. The triple combination pill increased the proportion achieving target BP vs usual care at 6 months (70% vs 55%, respectively; risk difference, 12.7% [95% CI, 3.2% to 22.0%]; P < .001). Mean systolic/diastolic BP at 6 months was 125/76 mm Hg for the triple combination pill vs 134/81 mm Hg for usual care (adjusted difference in postrandomization BP over the entire follow-up: systolic BP, -9.8 [95% CI, -7.9 to -11.6] mm Hg; diastolic BP, -5.0 [95% CI, -3.9 to -6.1] mm Hg; P < .001 for both comparisons). Overall, 419 adverse events were reported in 255 patients (38.1% for triple combination pill vs 34.8% for usual care) with the most common being musculoskeletal pain (6.0% and 8.0%, respectively) and dizziness, presyncope, or syncope (5.2% and 2.8%). There were no significant between-group differences in the proportion of patient withdrawal from BP-lowering therapy due to adverse events (6.6% for triple combination pill vs 6.8% for usual care). CONCLUSIONS AND RELEVANCE Among patients with mild to moderate hypertension, treatment with a pill containing low doses of 3 antihypertensive drugs led to an increased proportion of patients achieving their target BP goal vs usual care. Use of such medication as initial therapy or to replace monotherapy may be an effective way to improve BP control. TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12612001120864; slctr.lk Identifier: SLCTR/2015/020.
Collapse
Affiliation(s)
- Ruth Webster
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Abdul Salam
- The George Institute for Global Health, University of New South Wales, Hyderabad, India
| | - H. Asita de Silva
- Clinical Trials Unit, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
| | - Vanessa Selak
- Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
| | - Sandrine Stepien
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Senaka Rajapakse
- Department of Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
| | | | | | - Laurent Billot
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Arjuna P. de Silva
- Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
| | | | - Rama Guggilla
- General Directorate of Health Affairs in Jizan, Ministry of Health, Sabya, Saudi Arabia
| | - Stephen Jan
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | | | - Pallab K. Maulik
- The George Institute for Global Health, University of New South Wales, New Delhi, India
| | | | | | | | - Nitish Naik
- All India Institute of Medical Sciences, New Delhi
| | | | | | - Simon Thom
- International Centre for Circulatory Health, Imperial College London, London, England
| | | | | | - Sanjeewa Wijekoon
- Department of Medicine, Faculty of Medical Sciences, University of Sri Jayawardenapura, Nugegoda, Sri Lanka
| | | | - Anthony Rodgers
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Anushka Patel
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| |
Collapse
|